Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Mar. 24, 2019 | Jun. 30, 2018 | |
Document Information [Line Items] | |||
Entity Registrant Name | NOVABAY PHARMACEUTICALS, INC. | ||
Entity Central Index Key | 0001389545 | ||
Trading Symbol | nby | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Non-accelerated Filer | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Emerging Growth Company | false | ||
Entity Small Business | true | ||
Entity Common Stock, Shares Outstanding (in shares) | 17,089,304 | ||
Entity Public Float | $ 12,878,993 | ||
Entity Shell Company | false | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2018 | ||
Document Fiscal Year Focus | 2018 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Current assets: | ||
Cash and cash equivalents | $ 3,183 | $ 3,199 |
Accounts receivable, net of allowance for doubtful accounts ($10 and $13 at December 31, 2018 and December 31, 2017, respectively) | 3,385 | 3,629 |
Inventory, net of allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments of $104 and $140 at December 31, 2018 and December 31, 2017, respectively) | 280 | 504 |
Prepaid expenses and other current assets | 1,760 | 1,663 |
Total current assets | 8,608 | 8,995 |
Property and equipment, net | 201 | 471 |
Other assets | 552 | 613 |
TOTAL ASSETS | 9,361 | 10,079 |
Current liabilities: | ||
Accounts payable | 551 | 466 |
Accrued liabilities | 3,255 | 1,672 |
Deferred revenue | 41 | 75 |
Total current liabilities | 3,847 | 4,979 |
Deferred revenues - non-current | 534 | |
Deferred rent | 184 | 286 |
Warrant liability | 178 | 1,489 |
Other liabilities | 198 | 197 |
Total liabilities | 4,407 | 7,485 |
Stockholders' equity : | ||
Preferred stock: 5,000 shares authorized; none outstanding at December 31, 2018 and December 31, 2017 | 0 | 0 |
Common stock, $0.01 par value; 50,000 and 240,000 shares authorized; 17,089 and 15,385 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively | 171 | 154 |
Additional paid-in capital | 119,764 | 113,514 |
Accumulated deficit | (114,981) | (111,074) |
Total stockholders' equity | 4,954 | 2,594 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ 9,361 | 10,079 |
Previously Reported [Member] | ||
Current liabilities: | ||
Deferred revenue | $ 2,841 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Accounts receivable, allowance for doubtful accounts | $ 10 | $ 13 |
Inventory, allowance for excess and obsolete inventory and lower of cost or estimated net realizable value adjustments | $ 104 | $ 140 |
Preferred stock, shares authorized (in shares) | 5,000,000 | 5,000,000 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Common stock, shares authorized (in shares) | 50,000,000 | 240,000,000 |
Common stock, shares issued (in shares) | 17,089,000 | 15,385,000 |
Common stock, shares outstanding (in shares) | 17,089,000 | 15,385,000 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Sales: | |||
Total sales, net | $ 12,508 | $ 18,230 | $ 11,897 |
Product cost of goods sold | 1,503 | 2,784 | 2,464 |
Gross profit | 11,005 | 15,446 | 9,433 |
Research and development | 259 | 410 | 1,371 |
Sales and marketing | 12,789 | 13,711 | 11,809 |
General and administrative | 5,828 | 8,636 | 7,235 |
Total operating expenses | 18,876 | 22,757 | 20,415 |
Operating loss | (7,871) | (7,311) | (10,982) |
Non-cash gain (loss) on changes in fair value of warrant liability | 1,311 | (101) | (2,099) |
Other income (expense), net | 19 | 12 | (68) |
Loss before provision for income taxes | (6,541) | (7,400) | (13,149) |
Provision for income tax | (4) | (3) | (2) |
Net income loss and comprehensive loss | $ (6,545) | $ (7,403) | $ (13,151) |
Net loss per share attributable to common stockholders (basic) (in dollars per share) | $ (0.39) | $ (0.48) | $ (1.40) |
Net loss per share attributable to common stockholders (diluted) (in dollars per share) | $ (0.46) | $ (0.48) | $ (1.40) |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (basic) (in shares) | 16,921 | 15,324 | 9,408 |
Weighted-average shares of common stock outstanding used in computing net loss per share of common stock (diluted) (in shares) | 17,058 | 15,324 | 9,408 |
Product [Member] | |||
Sales: | |||
Total sales, net | $ 12,474 | $ 18,127 | $ 11,617 |
Product and Service, Other [Member] | |||
Sales: | |||
Total sales, net | $ 34 | $ 103 | $ 280 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands | Employee [Member]Common Stock [Member] | Employee [Member]Additional Paid-in Capital [Member] | Employee [Member]AOCI Attributable to Parent [Member] | Employee [Member]Retained Earnings [Member] | Employee [Member] | Nonemployees [Member]Common Stock [Member] | Nonemployees [Member]Additional Paid-in Capital [Member] | Nonemployees [Member]AOCI Attributable to Parent [Member] | Nonemployees [Member]Retained Earnings [Member] | Nonemployees [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2015 | 3,486,000 | ||||||||||||||
Balance at Dec. 31, 2015 | $ 35 | $ 85,387 | $ (90,520) | $ (5,098) | |||||||||||
Net loss | (13,151) | (13,151) | |||||||||||||
Issuance of stock and warrants, net of offering costs (in shares) | 7,692,000 | ||||||||||||||
Issuance of stock and warrants, net of offering costs | $ 77 | 13,571 | 13,648 | ||||||||||||
Issuance of common stock in connection with exercise of warrants, net of offering costs (in shares) | 3,977,000 | ||||||||||||||
Issuance of common stock in connection with exercise of warrants, net of offering costs | $ 40 | 7,389 | 7,429 | ||||||||||||
Fair market value of warrants transferred to equity upon exercise | 2,103 | 2,103 | |||||||||||||
Warrant modification | 270 | 270 | |||||||||||||
Issuance of stock to consultants for services (in shares) | 2,000 | ||||||||||||||
Issuance of stock to consultants for services | 8 | 8 | |||||||||||||
Vesting of restricted stock awards (in shares) | 73,000 | 41,000 | |||||||||||||
Vesting of restricted stock awards | $ 1 | $ 173 | $ 174 | $ 133 | $ 133 | ||||||||||
Shares retired as result of reverse stock split (in shares) | (2,000) | ||||||||||||||
Stock-based compensation expense related to employee and director stock options | 1,316 | 1,316 | |||||||||||||
Stock-based compensation expense related to non-employee and director stock options | 269 | $ 269 | |||||||||||||
Issuance of stock for option exercises (in shares) | 0 | ||||||||||||||
Cumulative effect of adoption of new accounting standard | |||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 15,269,000 | ||||||||||||||
Balance at Dec. 31, 2016 | $ 153 | 110,619 | (103,671) | 7,101 | |||||||||||
Net loss | (7,403) | (7,403) | |||||||||||||
Issuance of common stock in connection with exercise of warrants, net of offering costs (in shares) | 21,000 | ||||||||||||||
Issuance of common stock in connection with exercise of warrants, net of offering costs | 97 | 97 | |||||||||||||
Issuance of stock to consultants for services (in shares) | 1,000 | ||||||||||||||
Issuance of stock to consultants for services | |||||||||||||||
Vesting of restricted stock awards (in shares) | 26,000 | ||||||||||||||
Vesting of restricted stock awards | 106 | 106 | |||||||||||||
Stock-based compensation expense related to employee and director stock options | 1,867 | 1,867 | |||||||||||||
Stock-based compensation expense related to non-employee and director stock options | 137 | $ 137 | |||||||||||||
Issuance of stock for option exercises (in shares) | 68,000 | 68,000 | |||||||||||||
Issuance of stock for option exercises | $ 1 | 184 | $ 185 | ||||||||||||
Stock option modification | 504 | 504 | |||||||||||||
Cumulative effect of adoption of new accounting standard | |||||||||||||||
Balance (in shares) at Dec. 31, 2017 | 15,385,000 | ||||||||||||||
Balance at Dec. 31, 2017 | $ 154 | 113,514 | (111,074) | 2,594 | |||||||||||
Net loss | (6,545) | (6,545) | |||||||||||||
Stock-based compensation expense related to employee and director stock options | 594 | $ 594 | |||||||||||||
Issuance of stock for option exercises (in shares) | 4,000 | 4,000 | |||||||||||||
Issuance of stock for option exercises | 11 | $ 11 | |||||||||||||
Stock option modification | 77 | 77 | |||||||||||||
Issuance of common stock in connection with offering (in shares) | 1,700,000 | ||||||||||||||
Issuance of common stock in connection with offering | $ 17 | 5,967 | 5,984 | ||||||||||||
Offering costs | (399) | (399) | |||||||||||||
Cumulative effect of adoption of new accounting standard | 2,638 | 2,638 | |||||||||||||
Balance (in shares) at Dec. 31, 2018 | 17,089,000 | ||||||||||||||
Balance at Dec. 31, 2018 | $ 171 | $ 119,764 | $ (114,981) | $ 4,954 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Operating activities: | |||
Net loss | $ (6,545,000) | $ (7,403,000) | $ (13,151,000) |
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Depreciation and amortization | 266,000 | 95,000 | 114,000 |
Loss (gain) on disposal of property and equipment | 1,000 | (219,000) | |
Warrant modification | 270,000 | ||
Stock option modification expense | 77,000 | 504,000 | |
Note receivable impairment | 91,000 | ||
Leasehold improvements impairment | 70,000 | ||
Non-cash (gain) loss on change in fair value of warrant liability | (1,311,000) | 101,000 | 2,099,000 |
Changes in operating assets and liabilities: | |||
Accounts receivable | 774,000 | (1,509,000) | (1,585,000) |
Inventory | 198,000 | 369,000 | 472,000 |
Prepaid expenses and other assets | (97,000) | 313,000 | (1,470,000) |
Other assets long-term | 62,000 | (73,000) | |
Accounts payable and accrued liabilities | 516,000 | (260,000) | (2,356,000) |
Deferred rent | (69,000) | 27,000 | 327,000 |
Deferred revenue | (34,000) | (472,000) | 1,641,000 |
Deferred taxes | 87,000 | ||
Long-term obligations | 198,000 | ||
Net cash used in operating activities | (5,568,000) | (6,270,000) | (11,661,000) |
Investing activities: | |||
Purchases of property and equipment | (44,000) | (244,000) | (160,000) |
Net cash used by investing activities | (44,000) | (244,000) | (160,000) |
Financing activities: | |||
Proceeds from common stock issuances, net | 5,585,000 | 13,648,000 | |
Proceeds from exercise of warrants, net | 38,000 | 7,429,000 | |
Proceeds from exercise of options, net | 11,000 | 185,000 | 0 |
Proceeds from stock options & RSUs sold to cover taxes | 1,000 | 26,000 | |
Settlement of restricted stock for tax withholding | (48,000) | ||
Proceeds from borrowings | 1,365,000 | ||
Repayment of borrowings | (3,020,000) | ||
Net cash provided by financing activities | 5,597,000 | 201,000 | 19,422,000 |
Net increase (decrease) in cash, cash equivalents, and restricted cash | (15,000) | (6,313,000) | 7,601,000 |
Cash, cash equivalents and restricted cash, beginning of period | 3,673,000 | 9,986,000 | 2,385,000 |
Cash, cash equivalents and restricted cash, end of period | 3,658,000 | 3,673,000 | 9,986,000 |
Interest paid | 51,000 | ||
Cumulative effect of adoption of new accounting standard | 2,638,000 | ||
Stock issued to consultants for services, included in accounts payable and accrued liabilities | 1,000 | 8,000 | |
Fixed asset purchases included in accounts payable and accrued liabilities | (49,000) | (49,000) | 60,000 |
Equity transferred to warrant liability | 58,000 | 2,103,000 | |
Exchange of equipment for services | 279,000 | ||
Severance Paid in Restricted Stock Units to Non-employees [Member] | |||
Financing activities: | |||
Severance paid in RSU to non-employee | 69,000 | 140,000 | |
Employees and Directors [Member] | Employee Stock Option [Member] | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Stock-based compensation expense for options and stock issued | 594,000 | 1,867,000 | 1,316,000 |
Nonemployees [Member] | Employee Stock Option [Member] | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Stock-based compensation expense for options and stock issued | 137,000 | 129,000 | |
Nonemployees [Member] | Restricted Stock Units (RSUs) [Member] | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Issuance of RSUs | 34,000 | 133,000 | |
Employee [Member] | Restricted Stock Units (RSUs) [Member] | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||
Issuance of RSUs | $ 173,000 |
Note 1 - Organization
Note 1 - Organization | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | NOTE 1. NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two ® ® ® ® ® The Company was incorporated under the laws of the State of California on January 19, 2000, no July 1, 2002, February 2007, June 2010, April 2016, four single Effective December 18, 2015, 1 25 11 Liquidity Based primarily on the funds available at December 31, 2018, second 2019. 2018 2018 may 1 2 3 one 4 may 1 3 one one not may |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | NOTE 2. Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars. Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not not Additionally, prior period amounts in the accompanying consolidated statements of cash flow have also been reclassified to conform to current period presentation. The reclassifications did not Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2018, December 31, 2017, two Beginning fiscal 2018, No. 2016 18, Statement of Cash Flows (Topic 230 $474 December 31, 2017, $475 December 31, 2018. December 31, 2018 2017, not The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the same reported in the consolidated statement of cash flows: Year Ended December 31, 2018 2017 Cash and cash equivalents $ 3,183 $ 3,199 Restricted cash included in Other assets 475 474 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 3,658 $ 3,673 The restricted cash amount included in Other assets on the consolidated balance sheet represents amounts held as certificate of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. Concentrations of Credit Risk, Major Partners and Customers, and Suppliers Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the years ended December 31, 2018, 2017 2016 three As of December 31, 2018, December 31, 2017 December 31, 2016 10% Year Ended December 31, Major distribution or collaboration partner 2018 2017 2016 Distributer A 23 % 22 % 20 % Distributer B 26 % 23 % 22 % Distributer C 25 % 21 % 16 % Collaborator D * 10 % * *Not 10% As of December 31, 2018, December 31, 2017 10% Year Ended December 31, Major distribution or collaboration partner 2018 2017 Distributer A 32 % 25 % Distributer B 31 % 18 % Distributer C 23 % 23 % Collaborator D * 23 % *Not 10% The Company relies on two third not third may not Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on U.S. GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under U.S. GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 Level 2 Level 3 Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it unlikely a specific invoice will be collected. Management identifies amounts due that are in dispute, and it believes are unlikely to be collected at the end of each reporting period. At December 31, 2018 December 31, 2017, $10 $13 120 Inventory Inventory is comprised of ( 1 2 3 December 31, 2018 2017, $104 $140 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with U.S. GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may no December 31, 2018 2017. not Comprehensive Income (Loss) ASC 220, Comprehensive Income, Revenue Recognition Beginning January 1, 2018, 606, Revenue from Contracts with Customers The Company generates product revenue through product sales to its major distribution partners, a limited number of other distributors and via its webstore. Product supply is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a "sell-in" basis. Other revenue is primarily generated through commercial partner agreements with strategic partners for the development and commercialization of the Company's product candidates. The terms of the agreements typically include more than one In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. ● Product supply ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply ● Incremental discounts and product supply prepayments considered material rights to the customer The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer's or the Company's discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. Transaction Price The Company has both fixed and variable consideration. Under the Company's license arrangements, non-refundable upfront fees are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Product supply selling prices are identified as variable consideration subject to the constraint on variable consideration for estimated discounts, rebates, chargebacks and product returns. Funding of research and development activities are considered variable payments until such costs are reimbursed, at which point they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. For product supply under the Company's distribution arrangements, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company does not not 30 one one At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for arrangements that contain multiple performance obligations, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. When a contract contains more than one Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method. The Company's intellectual property in the form of distribution rights are determined to be distinct from the other performance obligations identified in the arrangements and considered "right to use" licenses which the customer can benefit from at a point in time. The Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license. Cost of Goods Sold Cost of goods sold includes third Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may no may Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Updates ("ASU") No. 2014 12, Compensation-Stock Compensation (Topic 718 ) 12 Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not Common Stock Warrant Liabilities For warrants that are newly issued or modified and there is a deemed possibility that the Company may Net Income (Loss) per Share The Company computes net income (loss) per share by presenting both basic and diluted earnings (loss) per share ("EPS"). Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing, diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During the year ended December 31, 2018, $0.39 $0.46 The following table sets forth the calculation of basic EPS and diluted EPS: Year Ended December 31, 2018 2017 2016 Numerator Net loss $ (6,545 ) $ (7,403 ) $ (13,151 ) Less gain on changes in fair value of warrant liability (1,311 ) — — Net loss, diluted $ (7,856 ) $ (7,403 ) $ (13,151 ) Denominator Weighted average shares outstanding, basic 16,921 15,324 9,408 Net loss per share, basic $ (0.39 ) $ (0.48 ) $ (1.40 ) Weighted average shares outstanding, basic 16,921 15,324 9,408 Effect of dilutive warrants 137 — — Weighted average shares outstanding, diluted 17,058 15,324 9,408 Net loss per share, diluted $ (0.46 ) $ (0.48 ) $ (1.40 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Year Ended December 31, (in thousands) 2018 2017 2016 Stock options 3,374 2,960 1,489 Stock warrants — 544 565 3,374 3,504 2,054 Recent Accounting Pronouncements In 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 606" 2015 2016, 606, 606, 606, December 15, 2017, one On January 1, 2018, 606 not January 1, 2018. not one January 1, 2018 606, not 605. 8 In November 2016, 2016 18, Statement of Cash Flows (Topic 230 one no one January 1, 2018 not In February 2016, 2016 02, Financial Accounting for Leases. 12 July 2018, 2018 11, Targeted Improvements not December 2018, 2018 20, Leases (Topic 842 December 15, 2018, not not 2018 11 not $2.2 $2.5 January 1, 2019 no July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 480 not December 15, 2018, 2017 11 January 1, 2019 not In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting (Topic 718 718 718 December 15, 2018, no 606. 2018 07 In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not |
Note 3 - Fair Value Measurement
Note 3 - Fair Value Measurements | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | NOTE 3. The Company measures the fair value of financial assets and liabilities based on authoritative guidance that defines fair value, establishes a framework consisting of three The Company's cash equivalents and investments are classified within Level 1 2 1 2 The Company's warrant liability is classified within level 3 The following table presents the Company's assets and liabilities measured at fair value on a recurring basis as of December 31, 2018: Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable (in thousands) 2018 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Cash equivalents $ 103 $ 103 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 578 $ 578 $ — $ — Liabilities Warrant liability $ 178 $ — $ — $ 178 Total liabilities $ 178 $ — $ — $ 178 The following table presents the Company's assets and liabilities measured at fair value on a recurring basis as of December 31, 2017: Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable (in thousands) 2017 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Cash equivalents $ 101 $ 101 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 575 $ 575 $ — $ — Liabilities Warrant liability $ 1,489 $ — $ — $ 1,489 Total liabilities $ 1,489 $ — $ — $ 1,489 For the year ended December 31, 2018, $1.3 10 (in thousands) 2018 2017 Fair value of warrant liability at January 1 $ 1,489 $ 1,446 Fair value of warrants issued — — Fair value of warrants transferred (to) from equity upon exercise — (58 ) Decrease in fair value on exercise date and December 31 (1,311 ) 101 Fair value of warrant liability at December 31 $ 178 $ 1,489 |
Note 4 - Prepaid Expenses and O
Note 4 - Prepaid Expenses and Other Current Assets | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Prepaid Expenses and Other Current Assets [Text Block] | NOTE 4. Prepaid expenses and other current assets consisted of the following: December 31, December 31, (in thousands) 2018 2017 Prepaid sales rebates $ 925 $ 923 Rent receivable 108 86 Prepaid rent 130 123 Prepaid employees’ benefits 113 112 Prepaid fleet leasing costs 75 61 Prepaid dues and subscription 130 4 Other 279 354 Total prepaid expenses and other current assets $ 1,760 $ 1,663 |
Note 5 - Inventory
Note 5 - Inventory | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | NOTE 5. Inventory consisted of the following: December 31, December 31, (in thousands) 2018 2017 Raw materials and supplies $ 217 $ 298 Finished goods 167 346 Less: Reserve for excess and obsolete inventory (104 ) (140 ) Total inventory, net $ 280 $ 504 |
Note 6 - Property and Equipment
Note 6 - Property and Equipment | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Property, Plant and Equipment Disclosure [Text Block] | NOTE 6. Property and equipment consisted of the following: December 31, December 31, (in thousands) 2018 2017 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 157 157 Computer equipment and software 385 354 Production equipment 65 105 Leasehold improvements 79 74 Total property and equipment, at cost 710 714 Less: accumulated depreciation and amortization (509 ) (243 ) Total property and equipment, net $ 201 $ 471 Depreciation and amortization expense was $266 $95 $114 December 31, 2018, 2017 2016, |
Note 7 - Accrued Liabilities
Note 7 - Accrued Liabilities | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | NOTE 7. Accrued liabilities consisted of the following: December 31, December 31, (in thousands) 2018 2017 Employee payroll and benefits $ 708 $ 761 Severance/retirement pay — 347 Distributer fees and discounts — 185 Sales rebates — 106 Avenova contract liabilities (see Note 8) 2,282 — Deferred rent 101 69 Other 164 204 Total accrued liabilities $ 3,255 $ 1,672 |
Note 8 - Adoption of Topic 606,
Note 8 - Adoption of Topic 606, "Revenue From Contracts With Customers" | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | NOTE 8. 606, On January 1, 2018, 606 not January 1, 2018. not one January 1, 2018 606, not 605. Transactions under the Company's major distribution agreements, which under prior guidance, were recognized upon shipment from its distributors to the final customers, are now recognized upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to. As a result, the Company now records contract liabilities for the invoiced amounts that are estimated to be subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. The constraint on variable consideration for product returns is a new estimation resulting from the earlier recognition under the new guidance. Based on this change, the entire deferred revenue and deferred cost of goods sold balances related to its distribution agreements were allocated to either contract liabilities and other liabilities associated with invoicing in periods prior to adoption or included in the cumulative adjustment to retained earnings upon adoption. Milestone payments, which under the prior milestone recognition methodology were not may not may The following table shows the reconciliation of assets and liabilities disclosed in the Form 10 December 31, 2017, 606 January 1, 2018 ( As Reported Effect of As Adjusted Under Change Under Topic 605 Topic 606 Accounts receivable $ 3,629 $ 530 $ 4,159 Inventory $ 504 $ (25 ) $ 479 Accrued liabilities $ 1,672 $ 1,166 $ 2,838 Deferred revenue $ 2,841 $ (2,766 ) $ 75 Deferred revenue, non-current $ 534 $ (534 ) $ - Accumulated deficit $ (111,074 ) $ 2,638 $ (108,436 ) As a result of adopting Topic 606 December 31, 2018, 605 As Reported Effect of As Revised Under Topic Change Under 606 Topic 605 Consolidated Balance Sheet: Accounts receivable $ 3,385 $ (358 ) $ 3,027 Inventory $ 280 $ 36 $ 316 Accrued liabilities $ 3,255 $ (1,979 ) $ 1,276 Deferred revenue $ 41 $ 3,853 $ 3,894 Accumulated deficit $ (114,981 ) $ (2,196 ) $ (117,177 ) Total net sales $ 12,508 $ 431 $ 12,939 Cost of product sales $ 1,503 $ (11 ) $ 1,492 Loss from operations $ (7,871 ) $ 442 $ (7,429 ) Net loss $ (6,545 ) $ 442 $ (6,103 ) Basic net loss per share $ (0.39 ) $ 0.03 $ (0.36 ) Diluted net loss per share $ (0.46 ) $ 0.03 $ (0.43 ) Consolidated Statement of Cash Flows: Net loss $ (6,545 ) $ 442 $ (6,103 ) Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable $ 774 $ (172 ) $ 602 Inventory $ 198 $ (11 ) $ 187 Accounts payable and accrued liabilities $ 516 $ (844 ) $ (328 ) Deferred revenue $ (34 ) $ 584 $ 550 At December 31, 2018, $41 2019. For additional detail on the Company's accounting policy regarding revenue recognition, refer to Note 2 The following table presents changes in the Company's contract assets and liabilities for the year ended December 31, 2018: Balance at Balance at Beginning the end of of the the year Additions Deductions year (in thousands) Contract Liabilities: Deferred Revenue $ 75 $ - $ (34 ) $ 41 Contract Liabilities: Accrued Liabilities 1,458 13,716 (12,817 ) 2,357 Total $ 1,533 $ 13,716 $ (12,851 ) $ 2,398 During the year ended December 31, 2018, Revenue recognized in the year from: Amounts included in contract liabilities at the beginning of the year: Performance obligations satisfied $ 1,453 New activities in the year: Performance obligations satisfied 11,055 Total revenue $ 12,508 License Collaboration and Distribution Agreements In January 2012, $312,500. $312,500 January 2013 first December 31, 2014, $625,000 In September 2012, two 1 2 one one Pursuant to the terms of the Distribution Agreement, China Pioneer has the right to distribute NeutroPhase, upon a marketing approval from a Regulatory Authority (as defined in the Distribution Agreement) in certain territories in Asia (other than China). Upon execution of the Distribution Agreement, the Company received an upfront payment, which was recorded as deferred revenue. China Pioneer is also obligated to make certain additional payments to the Company upon receipt of the marketing approval. The Distribution Agreement further provides that China Pioneer is entitled to a cumulative purchase discount not $500,000 Pursuant to the Purchase Agreement, the Company also received $2.5 one one two 1 800,000 September 2012; 2 1,200,000 October 2012, $1.25 $3.5 $2.5 $1 $600,000 In December 2013, 11 On February 7, 2012, $750,000. In April 2013, 422 $250,000. On June 1, 2013, $200,000. Revenue has been recognized under these agreements as follows: Year Ended December 31, (in thousands) 2018 2017 Amortization of upfront technology and access fees $ 34 $ 103 Product revenue 169 1,956 Total revenue recognized $ 203 $ 2,059 The Company had a deferred revenue balance of $2.0 December 31, 2017 606, $1.96 December 31, 2018, $41 Avenova Distribution Agreements In November 2014, January 2015, April 2015, During the years ended December 31, 2018 2017, $11.0 $13.6 The Company had a deferred revenue balance of $1.3 December 31, 2017 not 606, $1.3 $0.6 $0.7 606, At December 31, 2018, $2.4 7 |
Note 9 - Commitments and Contin
Note 9 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | NOTE 9. Operating Leases On August 24, 2016, 7,799 eleventh 1150 2000 94608 February 28, 2022, one five 5 no twelve 12 no nine 9 The Company still has a lease commitment for the laboratory facilities and office space at Suite 550, 5980 October 31, 2020. July 11, 2016, 16,465 September 8, 2016. October 21, 2020, October 31, 2020), Rent expense, net was $385 $389 $938 December 31, 2018, 2017 2016, December 31, 2018: (in thousands) Lease Commitment Year ending December 31: 2019 $ 1,116 2020 1,025 2021 438 2022 75 2023 - Thereafter - Total lease commitment $ 2,654 The Company's monthly rent payments fluctuate under the master lease agreements. In accordance with U.S. GAAP, the Company recognizes rent expense on a straight-line basis, and records deferred rent for the difference between the amounts paid and recorded as expense. At December 31, 2018 2017, $286 $355 Sub-lease rental reimbursement is not $690 $577 December 31, 2019 2020, Vehicle Fleet Leases During the year ended December 31, 2018, 54 36 December 31, 2018, 54 $14 $15 $3 36 Lease expense, net, for the vehicle fleet was approximately $120 $94 December 31, 2018 2017, Directors and Officers Indemnity As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company's request in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director or officer insurance policy that limits its exposure and may not December 31, 2018. In the normal course of business, the Company provides indemnifications of varying scope under its agreements with other companies, typically its clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third not December 31, 2018. Legal Matters From time to time, the Company may no December 31, 2018 |
Note 10 - Warrant Liability
Note 10 - Warrant Liability | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Other Liabilities Disclosure [Text Block] | NOTE 10. In July 2011, 139,520 $33.25 January 1, 2012 July 5, 2016. 480, Distinguishing Liabilities from Equity 480 January 5, 2012, $66.50 ten not fifteen one third In October 2015, March 3, 2015 ( "2015 twenty two March 3, 2016). October 2015 15 five 2015 "March 2015 June 29, 2011 ( "July 2011 March 2015 July 2011 $5.00 July 2011 March 6, 2020. July 2011 March 2015 $5.00 $5.00, In October 2015, 492,000 442,802 "October 2015 $5.00 "October 2015 60 October 2015 $5.00 $2.1 In February 2016, July 2011, March 2015 October 2015 $1.81 The key assumptions used to value the July 2011 December 31, 2018 December 31, 2017 Year Ended December 31, Assumption 2018 2017 Expected price volatility 77 % 91 % Expected term (in years) 1.18 2.18 Risk-free interest rate 2.60 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.29 $ 2.72 In March 2015, $15.00 $16.25 not March 2015 July 2011 October 2015, March 2015 March 2015 October 27, 2015 $1.8 October 27, 2015 October 27, 2015. The key assumptions used to value the Short-Term Warrants as of December 31, 2018, December 31, 2017 Year Ended December 31, Assumption 2018 2017 Expected price volatility 77 % 91 % Expected term (in years) 1.18 2.18 Risk-free interest rate 2.60 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.24 $ 2.42 The key assumptions used to value the Long-Term Warrants as of December 31, 2018, December 31, 2017 Year Ended December 31, Assumption 2018 2017 Expected price volatility 77 % 91 % Expected term (in years) 1.18 2.18 Risk-free interest rate 2.60 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.29 $ 2.72 As noted above, the Company issued warrants in connection with the October 2015 October 2015 480, 480 October 27, 2015 $1.3 The key assumptions used to value the October 2015 December 31, 2018, December 31, 2017 Year Ended December 31, Assumption 2018 2017 Expected price volatility 73 % 90 % Expected term (in years) 1.83 2.83 Risk-free interest rate 2.51 % 1.96 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.38 $ 2.86 During the third 2016, 3,613,284 3,613,284 July 2011, March 2015 October 2015 $6.9 $1.6 $1.6 During the fourth 2016, 363,523 363,523 October 2011, November 2015 December 2015 $0.9 $0.5 $0.5 During the second 2017, 21,000 21,000 March 2015 $38 $58 $58 The details of all outstanding warrant liability as of December 31, 2018, Shares and dollars in thousands Warrant Shares Liability July 2011 Warrants 49 $ 15 Long-Term Warrants 96 28 Short-Term Warrants 115 28 October 2015 Warrants 284 107 544 $ 178 |
Note 11 - Stockholders' Equity
Note 11 - Stockholders' Equity (Deficit) | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Stockholders' Equity Note Disclosure [Text Block] | NOTE 11. Amendments to Certificate of Incorporation – Reverse Stock Split Effective December 11, 2015, 1 25 December 11, 2015. After approval by the Company's stockholders, the Company decreased the number of authorized shares from 240 50 June 4, 2018. Preferred Stock Under the Company's Amended and Restated Certificate of Incorporation, the Company is authorized to issue up to 5,000,000 may December 31, 2018 December 31, 2017, no Common Stock In February 2016, three 1,518,567 $2.8 first 696,590 $1.81, five 5% February 16, 2016, second 696,590 $1.91, February 16, 2016 no third 125,387 $1.91, February 16, 2016 no not may not China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six 6% $155 On April 4, 2016, 6,173,299 $0.01 "April 2016 3,086,651 $11.8 "April 2016 4 $1.91, $4.00 five April 2016 two first May 5, 2016, $7.8 second August 1, 2016, $4.0 4,079,058 April 2016 2,039,530 2,094,241 April 2016 1,047,121 China Kington Asset Management Co. Ltd. served as placement agent in exchange for a commission equal to six 6% $618 Also on April 4, 2016, may April 2016 April 2016 June 9, 2016 June 20, 2016 ( 333 211943 During the third 2016, $6.6 3,613,284 3,613,284 May 2016 August 2016. six 6% $338 During the fourth 2016, $0.9 363,523 363,523 six 6% $32 During the first 2018, 1,700,000 $0.01 $5.984 February 8, 2018. six 6% $359 $34 Stock Warrants In February 2016, July 2011, March 2015 October 2015 $1.81 In May 2016, 2,039,530 In August 2016, 1,047,121 Effective September 29, 2016, May 18, 2015, $19.50 $3.15 sixteen 16% September 27, 2016. $270 The following table summarizes information about the Company's warrants outstanding at December 31, 2018, 2017 2016, three Weighted- Average Exercise (in thousands) Warrants Price Outstanding at December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 $ 1.91 Warrants exercised (3,977 ) $ 1.95 Warrants expired (3 ) $ 78.13 Outstanding at December 31, 2016 565 $ 1.81 Warrants granted - $ - Warrants exercised (21 ) $ 1.81 Warrants expired - $ - Outstanding at December 31, 2017 544 $ 1.81 Warrants granted - $ - Warrants exercised - $ - Warrants expired - $ - Outstanding at December 31, 2018 544 $ 1.81 |
Note 12 - Equity-based Compensa
Note 12 - Equity-based Compensation | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | NOTE 12. Equity Compensation Plans In October 2007, 2007 "2007 2007 40,000 2007 For the years from 2009 2012, 2007 40,000 4% 40,000, 37,427, 37,207 2007 January 2012, 2011 2010, 2013, 40,000 2007 4% 32,646 59,157 2007 January 2014 2013, March 30, 2015, 82,461 2007 January 2016, 139,449 2007 2007 May 26, 2016, 2007 1,124,826 January 2017, 610,774 2007 2007 2007 2,318,486 March 15, 2017 ( 2007 Upon expiration of the 2007 2007 March 15, 2017 2007 may not 100% 10% not 110% 2007 no ten four In March 2017, 2017 "2017 June 2, 2017, 2017 not 2007 2017 2,318,486 first January 1, 2018 January 1, 2027 four 4 2017 December 31, 2018, 1,188,485 2017 Under the terms of the 2017 may not 100% 10% not 110% not ten not five ten four 2007 2017 Stock Option Summary The following table summarizes information about the Company's stock options and restricted stock outstanding at December 31, 2018, 2017 2016, three (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2015 388 $ 32.03 6.2 $ 19 Options granted 1,227 $ 2.74 Restricted stock units granted 104 $ — Options exercised - $ — Restricted stock units vested (114 ) $ — Options forfeited/cancelled (116 ) $ 28.27 Restricted stock units cancelled - $ — Outstanding at December 31, 2016 1,489 $ 8.38 8.7 $ 702 Options granted 1,616 $ 3.03 Restricted stock units granted 49 $ — Options exercised (68 ) $ 2.72 Restricted stock units vested (39 ) $ — Options forfeited/cancelled (87 ) $ 22.08 Restricted stock units cancelled - $ — Outstanding at December 31, 2017 2,960 $ 5.16 8.6 $ 2,586 Options granted 1,118 $ 2.03 Restricted stock units granted 12 $ — Options exercised (4 ) $ 2.35 Restricted stock units vested - $ — Options forfeited/cancelled (701 ) $ 5.12 Restricted stock units cancelled (11 ) $ — Outstanding at December 31, 2018 3,374 $ 4.13 8.2 $ 8 Vested and expected to vest at December 31, 2018 2,898 $ 4.40 8.2 $ 8 Vested at December 31, 2018 1,675 $ 5.96 7.4 $ — Exercisable at December 31, 2018 1,675 $ 5.96 7.4 $ — The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company's common stock as quoted on the NYSE American as of December 31, 2018 4 December 31, 2018 $11 no December 31, 2018. 68 December 31, 2017 $185 $116 December 31, 2017. no December 31, 2016. no December 31, 2016. December 31, 2018, $1.7 3.01 Stock Option Awards to Employees and Directors The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes-Merton option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2 During the years ended December 31, 2018, 2017 2016, 1,085,000, 1,529,000, 1,139,000 The weighted-average assumptions used in determining the value of options are as follows: Year Ended December 31, Assumption 2018 2017 2016 Expected price volatility 89.30 % 87.78 % 84.47 % Expected term (in years) 5.98 6.90 7.03 Risk-free interest rate 2.80 % 2.12 % 1.57 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.51 $ 2.34 $ 2.06 Expected Price Volatility Expected Term Risk-Free Interest Rate Dividend Yield not Forfeitures are estimated at the time of grant and reduce compensation expense ratably over the vesting period. This estimate is adjusted periodically based on the extent to which actual forfeitures differ, or are expected to differ, from the previous estimate. In addition, the Company granted restricted stock to employees totaling 12,000, 10,000, 64,000 December 31, 2018, 2017 2016, For the years ended December 31, 2018, 2017 2016, $671 $2,371 $1,489 During the second third 2016, two May 6, 2016 August 24, 2016, three four $58 In July 2017, December 31, 2017. three three third 2017 December 31, 2017, third fourth 2017. $244 three September 30, 2017 $260 three December 31, 2017. In March 2018, March 21, 2018. three three $26 Stock-Based Awards to Non-Employee Consultants During the years ended December 31, 2018, 2017 2016, 33,000, 86,000, 89,000 Year Ended December 31, Assumption 2018 2017 2016 Expected price volatility 85.03 % 87.41 % 87.68 % Expected term (in years) 10.0 10.0 10.0 Risk-free interest rate 2.94 % 2.27 % 1.61 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.99 $ 2.40 $ 2.29 The Company did not December 31, 2018. 31 December 31, 2017, 8 December 31, 2017, 41,000 December 31, 2016, For the years ended December 31, 2018, 2017 2016, $0, $243 $262 In November 2015, December 2016, 2016. December 31, 2015, December 2016. January 2017, In March 2016, March 2016, December 31, 2015 March 2016. Summary of Stock-Based Compensation Expense A summary of the stock-based compensation expense included in the consolidated statement of operations and comprehensive loss for the options and common stock discussed above is as follows. The amounts that would have been charged to cost of goods sold are not Year Ended December 31, (in thousands) 2018 2017 2016 Research and development $ 32 $ 113 $ 195 Sales and Marketing 141 152 132 General and administrative 498 2,277 1,424 Total stock-based compensation expense $ 671 $ 2,542 $ 1,751 Since the Company continues to operate at a net loss, it does not |
Note 13 - Employee Benefit Plan
Note 13 - Employee Benefit Plan | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Pension and Other Postretirement Benefits Disclosure [Text Block] | NOTE 13. We have a 401 not December 31, 2018 2017, $14 $0 |
Note 14 - Income Taxes
Note 14 - Income Taxes | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 14. The federal and state income tax provision is summarized as follows (in thousands): Year Ending December (in thousands) 2018 2017 2016 Current Federal $ — $ — $ — State 4 3 2 Other — — — Total current tax expense 4 3 2 Deferred Federal — — — State — — — Other — — — Total deferred tax expense — — — Income tax provision $ 4 $ 3 $ 2 Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards. The tax effects of significant items comprising the Company's deferred taxes as of December 31 December 31 (in thousands) 2018 2017 Deferred tax assets: Net operating losses $ 26,790 $ 25,564 Accruals 446 225 Deferred revenue 10 508 Stock options 1,425 1,556 Other deferred tax assets 716 727 Property and equipment 9 — Total deferred tax assets 29,396 28,580 Deferred tax liabilities: Property and equipment — (35 ) Total deferred tax liabilities — (35 ) Valuation allowance (29,396 ) (28,545 ) Net deferred taxes $ — $ — On December 22, 2017, 2017 35% 21% December 31, 2017. December 31, 2017 The Company records the tax benefit of net operating loss carryforwards and temporary differences as an asset to the extent that management assesses that realization is "more likely than not." not The valuation allowance (decreased)/increased by the following amounts (in thousands): 2018 2017 2016 $ 851 $ (10,100 ) $ 3,642 Net operating loss and tax credit carryforwards as of December 31, 2018, Expiration Amount Years Net operating losses, federal (Post December 31, 2017) $ 5,216 Do Not Expire Net operating losses, federal (Pre January 1, 2018) $ 94,886 2024 - 2037 Net operating losses, state $ 84,078 2028 - 2038 Tax credits, federal $ 1,316 2026 - 2035 Tax credits, state $ 325 Indefinite Under U.S. federal tax law, the amount and availability of tax benefits are subject to a variety of interpretations and restrictive tests. Utilization of the net operating loss (NOL) carryforwards may 382 1986, may 382, 50 three two may one 382. not may not 382. no The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal statutory rate as follows: Year Ending December 31 (in thousands) 2018 2017 2016 Income tax provision (benefit) at federal statutory rate $ (1,374 ) $ (2,516 ) $ (4,471 ) State tax 20 (12 ) (157 ) Stock based compensation expense for GAAP 283 154 52 Change in valuation allowance 851 (10,484 ) 3,641 Revaluation of warrant liability (275 ) 34 806 Tax credits — — (31 ) Other 33 (49 ) 162 Section 162(m) disallowance (88 ) 336 — Tax Reform - Tax Rate Change — 12,540 — Impact of ASC 606 554 — — Total $ 4 $ 3 $ 2 Uncertain Income Tax Positions The Company adopted the provisions of ASC 740 10, Accounting for Uncertainty in Income Taxes January 1, 2007. no December 31, 2018 2017 Year ended December 31, (in thousands) 2018 2017 Unrecognized benefit - beginning of period $ 931 $ 974 Gross increases/ (decreases) - prior/current period tax positions 43 (43 ) Unrecognized benefit - end of period $ 974 $ 931 Our policy will be to recognize interest and penalties related to income taxes as a component of income tax expense. We are subject to income tax examinations for U.S. incomes taxes and state income taxes from 2004 2006 not 12 |
Note 15 - Related Party Transac
Note 15 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | NOTE 15. Related Party Revenue The Company recognized related party revenues from product sales and license and collaboration fees of $77 $27 $418 December 31, 2018, 2017 2016, $426 $102 $0 December 31, 2018, 2017 2016, December 31, 2018 $39 no December 31, 2017. 8, 606, Revenue from contracts with customers Related Party Expenses The Company recognized related party commission fees of $0.4 $0, $1.1 December 31, 2018, 2017 2016, 11, Related Party Financing On February 27, 2019, February 2019 16 |
Note 16 - Subsequent Events
Note 16 - Subsequent Events | 12 Months Ended |
Dec. 31, 2018 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | NOTE 16. As disclosed in our Current Reports on Form 8 March 11, 2019 March 12, 2019, On February 27, 2019, $1.0 “February 2019 $150 no July 27, 2019. February 2019 2% one $100,000 On March 25, 2019, $3,000,000 90% five 150,000 $15,000. 3 April 1, 2019 On March 26, 2019 ( $2,215,000, 10% September 26, 2020, $2,000,000 The Convertible Note provides the Lender with the right to convert, at any time, all or any part of the outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price of $1.65 85% twenty 20 Pursuant to a Security Agreement between the Company and the Lender, repayment of the Convertible Note is secured by all of the assets of the Company. The assets covered by the Security Agreement are currently encumbered by that certain lien of up to $1,000,000, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2018 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") and are expressed in U.S. dollars. |
Reclassification, Policy [Policy Text Block] | Reclassifications Prior period amounts in the accompanying consolidated balance sheets have been reclassified to conform to current period presentation. The reclassifications did not not Additionally, prior period amounts in the accompanying consolidated statements of cash flow have also been reclassified to conform to current period presentation. The reclassifications did not |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates include useful lives for property and equipment and related depreciation calculations, estimated amortization periods for payments received from product development and license agreements as they relate to revenue recognition, assumptions for valuing options and warrants, and income taxes. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents The Company considers all highly-liquid instruments with a stated maturity of three December 31, 2018, December 31, 2017, two Beginning fiscal 2018, No. 2016 18, Statement of Cash Flows (Topic 230 $474 December 31, 2017, $475 December 31, 2018. December 31, 2018 2017, not The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the consolidated balance sheet that sum to the total of the same reported in the consolidated statement of cash flows: Year Ended December 31, 2018 2017 Cash and cash equivalents $ 3,183 $ 3,199 Restricted cash included in Other assets 475 474 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 3,658 $ 3,673 The restricted cash amount included in Other assets on the consolidated balance sheet represents amounts held as certificate of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord. |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentrations of Credit Risk, Major Partners and Customers, and Suppliers Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits of cash and cash equivalents with two Deposits in these banks may not During the years ended December 31, 2018, 2017 2016 three As of December 31, 2018, December 31, 2017 December 31, 2016 10% Year Ended December 31, Major distribution or collaboration partner 2018 2017 2016 Distributer A 23 % 22 % 20 % Distributer B 26 % 23 % 22 % Distributer C 25 % 21 % 16 % Collaborator D * 10 % * *Not 10% As of December 31, 2018, December 31, 2017 10% Year Ended December 31, Major distribution or collaboration partner 2018 2017 Distributer A 32 % 25 % Distributer B 31 % 18 % Distributer C 23 % 23 % Collaborator D * 23 % *Not 10% The Company relies on two third not third may not |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Assets and Liabilities Financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Our warrant liability is carried at fair value. The Company measures the fair value of financial assets and liabilities based on U.S. GAAP guidance, which defines fair value, establishes a framework for measuring fair value, and requires disclosures about fair value measurements. Under U.S. GAAP, fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is also established, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. There are three may Level 1 Level 2 Level 3 |
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block] | Allowance for Doubtful Accounts The Company charges bad debt expense and records an allowance for doubtful accounts when management believes it unlikely a specific invoice will be collected. Management identifies amounts due that are in dispute, and it believes are unlikely to be collected at the end of each reporting period. At December 31, 2018 December 31, 2017, $10 $13 120 |
Inventory, Policy [Policy Text Block] | Inventory Inventory is comprised of ( 1 2 3 December 31, 2018 2017, $104 $140 Inventory is stated at the lower of cost or estimated net realizable value determined by the first first |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five seven three seven seven The costs of normal maintenance, repairs, and minor replacements are charged to operations when incurred. |
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | Impairment of Long-Lived Assets The Company accounts for long-lived assets in accordance with U.S. GAAP, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may no December 31, 2018 2017. not |
Comprehensive Income, Policy [Policy Text Block] | Comprehensive Income (Loss) ASC 220, Comprehensive Income, |
Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition Beginning January 1, 2018, 606, Revenue from Contracts with Customers The Company generates product revenue through product sales to its major distribution partners, a limited number of other distributors and via its webstore. Product supply is the only performance obligation contained in these arrangements, and the Company recognizes product revenue upon transfer of control to its major distribution partners at the amount of consideration that the Company expects to be entitled to, generally upon shipment to the distributor on a "sell-in" basis. Other revenue is primarily generated through commercial partner agreements with strategic partners for the development and commercialization of the Company's product candidates. The terms of the agreements typically include more than one In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. ● Product supply ● Exclusive distribution rights in the product territory ● Regulatory submission and approval services ● Development services ● Sample supply ● Incremental discounts and product supply prepayments considered material rights to the customer The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer's or the Company's discretion are generally considered options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. Transaction Price The Company has both fixed and variable consideration. Under the Company's license arrangements, non-refundable upfront fees are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Product supply selling prices are identified as variable consideration subject to the constraint on variable consideration for estimated discounts, rebates, chargebacks and product returns. Funding of research and development activities are considered variable payments until such costs are reimbursed, at which point they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation. For product supply under the Company's distribution arrangements, contract liabilities are recorded for invoiced amounts that are subject to significant reversal, including product revenue allowances for cash consideration paid to customers for services, discounts, rebate programs, chargebacks, and product returns. Because the Company does not not 30 one one At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not not not For arrangements that include sales-based royalties and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Allocation of Consideration As part of the accounting for arrangements that contain multiple performance obligations, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. When a contract contains more than one Timing of Recognition Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method. The Company's intellectual property in the form of distribution rights are determined to be distinct from the other performance obligations identified in the arrangements and considered "right to use" licenses which the customer can benefit from at a point in time. The Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer, and the customer can use and benefit from the license. |
Cost of Goods Sold, Policy [Policy Text Block] | Cost of Goods Sold Cost of goods sold includes third |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Costs The Company charges research and development costs to expense as incurred. These costs include salaries and benefits for research and development personnel, costs associated with clinical trials managed by contract research organizations, and other costs associated with research, development and regulatory activities. Research and development costs may no may |
Patent Costs Policy [Policy Text Block] | Patent Costs Patent costs, including legal expenses, are expensed in the period in which they are incurred. Patent expenses are included in general and administrative expenses in the consolidated statements of operations and comprehensive loss. |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of Accounting Standards Updates ("ASU") No. 2014 12, Compensation-Stock Compensation (Topic 718 ) 12 |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not not |
Warrant Liabilities [Policy Text Block] | Common Stock Warrant Liabilities For warrants that are newly issued or modified and there is a deemed possibility that the Company may |
Earnings Per Share, Policy [Policy Text Block] | Net Income (Loss) per Share The Company computes net income (loss) per share by presenting both basic and diluted earnings (loss) per share ("EPS"). Basic EPS is computed by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing, diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods because their effect would be anti-dilutive. During the year ended December 31, 2018, $0.39 $0.46 The following table sets forth the calculation of basic EPS and diluted EPS: Year Ended December 31, 2018 2017 2016 Numerator Net loss $ (6,545 ) $ (7,403 ) $ (13,151 ) Less gain on changes in fair value of warrant liability (1,311 ) — — Net loss, diluted $ (7,856 ) $ (7,403 ) $ (13,151 ) Denominator Weighted average shares outstanding, basic 16,921 15,324 9,408 Net loss per share, basic $ (0.39 ) $ (0.48 ) $ (1.40 ) Weighted average shares outstanding, basic 16,921 15,324 9,408 Effect of dilutive warrants 137 — — Weighted average shares outstanding, diluted 17,058 15,324 9,408 Net loss per share, diluted $ (0.46 ) $ (0.48 ) $ (1.40 ) The following outstanding stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive: Year Ended December 31, (in thousands) 2018 2017 2016 Stock options 3,374 2,960 1,489 Stock warrants — 544 565 3,374 3,504 2,054 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 606" 2015 2016, 606, 606, 606, December 15, 2017, one On January 1, 2018, 606 not January 1, 2018. not one January 1, 2018 606, not 605. 8 In November 2016, 2016 18, Statement of Cash Flows (Topic 230 one no one January 1, 2018 not In February 2016, 2016 02, Financial Accounting for Leases. 12 July 2018, 2018 11, Targeted Improvements not December 2018, 2018 20, Leases (Topic 842 December 15, 2018, not not 2018 11 not $2.2 $2.5 January 1, 2019 no July 2017, 2017 11, Earnings Per Share (Topic 260 480 815 480 not December 15, 2018, 2017 11 January 1, 2019 not In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting (Topic 718 718 718 December 15, 2018, no 606. 2018 07 In August 2018, No. 2018 13, Fair Value Measurement (Topic 820 December 15, 2019, not |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] | Year Ended December 31, 2018 2017 Cash and cash equivalents $ 3,183 $ 3,199 Restricted cash included in Other assets 475 474 Total cash, cash equivalents, and restricted cash in the statement of cash flows $ 3,658 $ 3,673 |
Schedules of Concentration of Risk, by Risk Factor [Table Text Block] | Year Ended December 31, Major distribution or collaboration partner 2018 2017 2016 Distributer A 23 % 22 % 20 % Distributer B 26 % 23 % 22 % Distributer C 25 % 21 % 16 % Collaborator D * 10 % * Year Ended December 31, Major distribution or collaboration partner 2018 2017 Distributer A 32 % 25 % Distributer B 31 % 18 % Distributer C 23 % 23 % Collaborator D * 23 % |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Year Ended December 31, 2018 2017 2016 Numerator Net loss $ (6,545 ) $ (7,403 ) $ (13,151 ) Less gain on changes in fair value of warrant liability (1,311 ) — — Net loss, diluted $ (7,856 ) $ (7,403 ) $ (13,151 ) Denominator Weighted average shares outstanding, basic 16,921 15,324 9,408 Net loss per share, basic $ (0.39 ) $ (0.48 ) $ (1.40 ) Weighted average shares outstanding, basic 16,921 15,324 9,408 Effect of dilutive warrants 137 — — Weighted average shares outstanding, diluted 17,058 15,324 9,408 Net loss per share, diluted $ (0.46 ) $ (0.48 ) $ (1.40 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Year Ended December 31, (in thousands) 2018 2017 2016 Stock options 3,374 2,960 1,489 Stock warrants — 544 565 3,374 3,504 2,054 |
Note 3 - Fair Value Measureme_2
Note 3 - Fair Value Measurements (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable (in thousands) 2018 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Cash equivalents $ 103 $ 103 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 151 151 — — Total assets $ 578 $ 578 $ — $ — Liabilities Warrant liability $ 178 $ — $ — $ 178 Total liabilities $ 178 $ — $ — $ 178 Fair Value Measurements Using Balance at Quoted Prices in Significant Significant December 31, Active Markets Other Unobservable (in thousands) 2017 for Identical Observable Inputs Items Inputs (Level 3) (Level 1) (Level 2) Assets Cash equivalents $ 101 $ 101 $ — $ — Restricted cash held as a certificate of deposit 324 324 — — Deposit held as a certificate of deposit 150 150 — — Total assets $ 575 $ 575 $ — $ — Liabilities Warrant liability $ 1,489 $ — $ — $ 1,489 Total liabilities $ 1,489 $ — $ — $ 1,489 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | (in thousands) 2018 2017 Fair value of warrant liability at January 1 $ 1,489 $ 1,446 Fair value of warrants issued — — Fair value of warrants transferred (to) from equity upon exercise — (58 ) Decrease in fair value on exercise date and December 31 (1,311 ) 101 Fair value of warrant liability at December 31 $ 178 $ 1,489 |
Note 4 - Prepaid Expenses and_2
Note 4 - Prepaid Expenses and Other Current Assets (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] | December 31, December 31, (in thousands) 2018 2017 Prepaid sales rebates $ 925 $ 923 Rent receivable 108 86 Prepaid rent 130 123 Prepaid employees’ benefits 113 112 Prepaid fleet leasing costs 75 61 Prepaid dues and subscription 130 4 Other 279 354 Total prepaid expenses and other current assets $ 1,760 $ 1,663 |
Note 5 - Inventory (Tables)
Note 5 - Inventory (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | December 31, December 31, (in thousands) 2018 2017 Raw materials and supplies $ 217 $ 298 Finished goods 167 346 Less: Reserve for excess and obsolete inventory (104 ) (140 ) Total inventory, net $ 280 $ 504 |
Note 6 - Property and Equipme_2
Note 6 - Property and Equipment (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Property, Plant and Equipment [Table Text Block] | December 31, December 31, (in thousands) 2018 2017 Office and laboratory equipment $ 24 $ 24 Furniture and fixtures 157 157 Computer equipment and software 385 354 Production equipment 65 105 Leasehold improvements 79 74 Total property and equipment, at cost 710 714 Less: accumulated depreciation and amortization (509 ) (243 ) Total property and equipment, net $ 201 $ 471 |
Note 7 - Accrued Liabilities (T
Note 7 - Accrued Liabilities (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | December 31, December 31, (in thousands) 2018 2017 Employee payroll and benefits $ 708 $ 761 Severance/retirement pay — 347 Distributer fees and discounts — 185 Sales rebates — 106 Avenova contract liabilities (see Note 8) 2,282 — Deferred rent 101 69 Other 164 204 Total accrued liabilities $ 3,255 $ 1,672 |
Note 8 - Adoption of Topic 60_2
Note 8 - Adoption of Topic 606, "Revenue From Contracts With Customers" (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Revenue, Initial Application Period Cumulative Effect Transition [Table Text Block] | As Reported Effect of As Adjusted Under Change Under Topic 605 Topic 606 Accounts receivable $ 3,629 $ 530 $ 4,159 Inventory $ 504 $ (25 ) $ 479 Accrued liabilities $ 1,672 $ 1,166 $ 2,838 Deferred revenue $ 2,841 $ (2,766 ) $ 75 Deferred revenue, non-current $ 534 $ (534 ) $ - Accumulated deficit $ (111,074 ) $ 2,638 $ (108,436 ) As Reported Effect of As Revised Under Topic Change Under 606 Topic 605 Consolidated Balance Sheet: Accounts receivable $ 3,385 $ (358 ) $ 3,027 Inventory $ 280 $ 36 $ 316 Accrued liabilities $ 3,255 $ (1,979 ) $ 1,276 Deferred revenue $ 41 $ 3,853 $ 3,894 Accumulated deficit $ (114,981 ) $ (2,196 ) $ (117,177 ) Total net sales $ 12,508 $ 431 $ 12,939 Cost of product sales $ 1,503 $ (11 ) $ 1,492 Loss from operations $ (7,871 ) $ 442 $ (7,429 ) Net loss $ (6,545 ) $ 442 $ (6,103 ) Basic net loss per share $ (0.39 ) $ 0.03 $ (0.36 ) Diluted net loss per share $ (0.46 ) $ 0.03 $ (0.43 ) Consolidated Statement of Cash Flows: Net loss $ (6,545 ) $ 442 $ (6,103 ) Adjustments to reconcile net loss to net cash used in operating activities: Accounts receivable $ 774 $ (172 ) $ 602 Inventory $ 198 $ (11 ) $ 187 Accounts payable and accrued liabilities $ 516 $ (844 ) $ (328 ) Deferred revenue $ (34 ) $ 584 $ 550 |
Contract with Customer, Asset and Liability [Table Text Block] | Balance at Balance at Beginning the end of of the the year Additions Deductions year (in thousands) Contract Liabilities: Deferred Revenue $ 75 $ - $ (34 ) $ 41 Contract Liabilities: Accrued Liabilities 1,458 13,716 (12,817 ) 2,357 Total $ 1,533 $ 13,716 $ (12,851 ) $ 2,398 |
Disaggregation of Revenue [Table Text Block] | Revenue recognized in the year from: Amounts included in contract liabilities at the beginning of the year: Performance obligations satisfied $ 1,453 New activities in the year: Performance obligations satisfied 11,055 Total revenue $ 12,508 |
Schedule of Revenue Recognized [Table Text Block] | Year Ended December 31, (in thousands) 2018 2017 Amortization of upfront technology and access fees $ 34 $ 103 Product revenue 169 1,956 Total revenue recognized $ 203 $ 2,059 |
Note 9 - Commitments and Cont_2
Note 9 - Commitments and Contingencies (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | (in thousands) Lease Commitment Year ending December 31: 2019 $ 1,116 2020 1,025 2021 438 2022 75 2023 - Thereafter - Total lease commitment $ 2,654 |
Note 10 - Warrant Liability (Ta
Note 10 - Warrant Liability (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Derivative Instruments [Table Text Block] | Year Ended December 31, Assumption 2018 2017 Expected price volatility 77 % 91 % Expected term (in years) 1.18 2.18 Risk-free interest rate 2.60 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.29 $ 2.72 Year Ended December 31, Assumption 2018 2017 Expected price volatility 77 % 91 % Expected term (in years) 1.18 2.18 Risk-free interest rate 2.60 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.24 $ 2.42 Year Ended December 31, Assumption 2018 2017 Expected price volatility 77 % 91 % Expected term (in years) 1.18 2.18 Risk-free interest rate 2.60 % 1.91 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.29 $ 2.72 Year Ended December 31, Assumption 2018 2017 Expected price volatility 73 % 90 % Expected term (in years) 1.83 2.83 Risk-free interest rate 2.51 % 1.96 % Dividend yield 0.00 % 0.00 % Weighted-average fair value of warrants $ 0.38 $ 2.86 |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Weighted- Average Exercise (in thousands) Warrants Price Outstanding at December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 $ 1.91 Warrants exercised (3,977 ) $ 1.95 Warrants expired (3 ) $ 78.13 Outstanding at December 31, 2016 565 $ 1.81 Warrants granted - $ - Warrants exercised (21 ) $ 1.81 Warrants expired - $ - Outstanding at December 31, 2017 544 $ 1.81 Warrants granted - $ - Warrants exercised - $ - Warrants expired - $ - Outstanding at December 31, 2018 544 $ 1.81 |
July 2011, Long-term, Short-term, and October 2015 Warrants [Member] | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Shares and dollars in thousands Warrant Shares Liability July 2011 Warrants 49 $ 15 Long-Term Warrants 96 28 Short-Term Warrants 115 28 October 2015 Warrants 284 107 544 $ 178 |
Note 11 - Stockholders' Equit_2
Note 11 - Stockholders' Equity (Deficit) (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Weighted- Average Exercise (in thousands) Warrants Price Outstanding at December 31, 2015 1,458 $ 5.19 Warrants granted 3,087 $ 1.91 Warrants exercised (3,977 ) $ 1.95 Warrants expired (3 ) $ 78.13 Outstanding at December 31, 2016 565 $ 1.81 Warrants granted - $ - Warrants exercised (21 ) $ 1.81 Warrants expired - $ - Outstanding at December 31, 2017 544 $ 1.81 Warrants granted - $ - Warrants exercised - $ - Warrants expired - $ - Outstanding at December 31, 2018 544 $ 1.81 |
Note 12 - Equity-based Compen_2
Note 12 - Equity-based Compensation (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Share-based Compensation, Stock Options, Activity [Table Text Block] | (in thousands, except years and per share data) Options Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding at December 31, 2015 388 $ 32.03 6.2 $ 19 Options granted 1,227 $ 2.74 Restricted stock units granted 104 $ — Options exercised - $ — Restricted stock units vested (114 ) $ — Options forfeited/cancelled (116 ) $ 28.27 Restricted stock units cancelled - $ — Outstanding at December 31, 2016 1,489 $ 8.38 8.7 $ 702 Options granted 1,616 $ 3.03 Restricted stock units granted 49 $ — Options exercised (68 ) $ 2.72 Restricted stock units vested (39 ) $ — Options forfeited/cancelled (87 ) $ 22.08 Restricted stock units cancelled - $ — Outstanding at December 31, 2017 2,960 $ 5.16 8.6 $ 2,586 Options granted 1,118 $ 2.03 Restricted stock units granted 12 $ — Options exercised (4 ) $ 2.35 Restricted stock units vested - $ — Options forfeited/cancelled (701 ) $ 5.12 Restricted stock units cancelled (11 ) $ — Outstanding at December 31, 2018 3,374 $ 4.13 8.2 $ 8 Vested and expected to vest at December 31, 2018 2,898 $ 4.40 8.2 $ 8 Vested at December 31, 2018 1,675 $ 5.96 7.4 $ — Exercisable at December 31, 2018 1,675 $ 5.96 7.4 $ — |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Year Ended December 31, (in thousands) 2018 2017 2016 Research and development $ 32 $ 113 $ 195 Sales and Marketing 141 152 132 General and administrative 498 2,277 1,424 Total stock-based compensation expense $ 671 $ 2,542 $ 1,751 |
Nonemployees [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Year Ended December 31, Assumption 2018 2017 2016 Expected price volatility 85.03 % 87.41 % 87.68 % Expected term (in years) 10.0 10.0 10.0 Risk-free interest rate 2.94 % 2.27 % 1.61 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.99 $ 2.40 $ 2.29 |
Employees and Directors [Member] | |
Notes Tables | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | Year Ended December 31, Assumption 2018 2017 2016 Expected price volatility 89.30 % 87.78 % 84.47 % Expected term (in years) 5.98 6.90 7.03 Risk-free interest rate 2.80 % 2.12 % 1.57 % Dividend yield 0.00 % 0.00 % 0.00 % Weighted-average fair value of options granted during the period $ 1.51 $ 2.34 $ 2.06 |
Note 14 - Income Taxes (Tables)
Note 14 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2018 | |
Notes Tables | |
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] | Year Ending December (in thousands) 2018 2017 2016 Current Federal $ — $ — $ — State 4 3 2 Other — — — Total current tax expense 4 3 2 Deferred Federal — — — State — — — Other — — — Total deferred tax expense — — — Income tax provision $ 4 $ 3 $ 2 |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31 (in thousands) 2018 2017 Deferred tax assets: Net operating losses $ 26,790 $ 25,564 Accruals 446 225 Deferred revenue 10 508 Stock options 1,425 1,556 Other deferred tax assets 716 727 Property and equipment 9 — Total deferred tax assets 29,396 28,580 Deferred tax liabilities: Property and equipment — (35 ) Total deferred tax liabilities — (35 ) Valuation allowance (29,396 ) (28,545 ) Net deferred taxes $ — $ — |
Summary of Valuation Allowance [Table Text Block] | 2018 2017 2016 $ 851 $ (10,100 ) $ 3,642 |
Summary of Operating Loss Carryforwards and Tax Credit Carryforwards [Table Text Block] | Expiration Amount Years Net operating losses, federal (Post December 31, 2017) $ 5,216 Do Not Expire Net operating losses, federal (Pre January 1, 2018) $ 94,886 2024 - 2037 Net operating losses, state $ 84,078 2028 - 2038 Tax credits, federal $ 1,316 2026 - 2035 Tax credits, state $ 325 Indefinite |
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | Year Ending December 31 (in thousands) 2018 2017 2016 Income tax provision (benefit) at federal statutory rate $ (1,374 ) $ (2,516 ) $ (4,471 ) State tax 20 (12 ) (157 ) Stock based compensation expense for GAAP 283 154 52 Change in valuation allowance 851 (10,484 ) 3,641 Revaluation of warrant liability (275 ) 34 806 Tax credits — — (31 ) Other 33 (49 ) 162 Section 162(m) disallowance (88 ) 336 — Tax Reform - Tax Rate Change — 12,540 — Impact of ASC 606 554 — — Total $ 4 $ 3 $ 2 |
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] | Year ended December 31, (in thousands) 2018 2017 Unrecognized benefit - beginning of period $ 931 $ 974 Gross increases/ (decreases) - prior/current period tax positions 43 (43 ) Unrecognized benefit - end of period $ 974 $ 931 |
Note 1 - Organization (Details
Note 1 - Organization (Details Textual) | Dec. 18, 2015 | Dec. 11, 2015 | Dec. 31, 2018 |
Number of Operating Segments | 1 | ||
Reverse Stock Split [Member] | |||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 25 | 25 |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies (Details Textual) $ / shares in Units, $ in Thousands | 12 Months Ended | ||||
Dec. 31, 2018USD ($)$ / shares | Dec. 31, 2017USD ($)$ / shares | Dec. 31, 2016USD ($)$ / shares | Jan. 01, 2019USD ($) | Dec. 31, 2015USD ($) | |
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance | $ 3,658 | $ 3,673 | $ 9,986 | $ 2,385 | |
Number of Major Distributors | 3 | ||||
Number of Major Source Manufacturers | 2 | ||||
Allowance for Doubtful Accounts Receivable, Ending Balance | $ 10 | 13 | |||
Allowance for Doubtful Accounts, Past Due Period Threshold | 120 days | ||||
Inventory Valuation Reserves, Ending Balance | $ 104 | 140 | |||
Impairment of Long-Lived Assets Held-for-use | $ 0 | $ 0 | |||
Payment for Product Supply Period | 30 days | ||||
Earnings Per Share, Basic, Total | $ / shares | $ (0.39) | $ (0.48) | $ (1.40) | ||
Earnings Per Share, Diluted, Total | $ / shares | $ (0.46) | $ (0.48) | $ (1.40) | ||
Equipment [Member] | Minimum [Member] | |||||
Property, Plant and Equipment, Useful Life | 5 years | ||||
Equipment [Member] | Maximum [Member] | |||||
Property, Plant and Equipment, Useful Life | 7 years | ||||
Computer Equipment and Software [Member] | |||||
Property, Plant and Equipment, Useful Life | 3 years | ||||
Furniture and Fixtures [Member] | |||||
Property, Plant and Equipment, Useful Life | 7 years | ||||
Leasehold Improvements [Member] | Maximum [Member] | |||||
Property, Plant and Equipment, Useful Life | 7 years | ||||
Accounting Standards Update 2016-18 [Member] | |||||
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Ending Balance | $ 475 | $ 474 | |||
Accounting Standards Update 2016-02 [Member] | Subsequent Event [Member] | |||||
Operating Lease, Right-of-Use Asset | $ 2,200 | ||||
Operating Lease, Liability, Total | $ 2,500 |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies - Components of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Cash and cash equivalents | $ 3,183 | $ 3,199 | ||
Restricted cash included in Other assets | 475 | 474 | ||
Total cash, cash equivalents, and restricted cash in the statement of cash flows | $ 3,658 | $ 3,673 | $ 9,986 | $ 2,385 |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies - Revenues and Accounts Receivable From Major Distribution Partners and Customers (Details) - Customer Concentration Risk [Member] | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | ||
Revenue from Contract with Customer [Member] | Distributor A [Member] | ||||
distribution or collaboration partners | 23.00% | 22.00% | 20.00% | |
Revenue from Contract with Customer [Member] | Distributor B [Member] | ||||
distribution or collaboration partners | 26.00% | 23.00% | 22.00% | |
Revenue from Contract with Customer [Member] | Distributor C [Member] | ||||
distribution or collaboration partners | 25.00% | 21.00% | 16.00% | |
Revenue from Contract with Customer [Member] | Collaborator D [Member] | ||||
distribution or collaboration partners | 10.00% | |||
Accounts Receivable [Member] | Distributor A [Member] | ||||
distribution or collaboration partners | 32.00% | 25.00% | ||
Accounts Receivable [Member] | Distributor B [Member] | ||||
distribution or collaboration partners | 31.00% | 18.00% | ||
Accounts Receivable [Member] | Distributor C [Member] | ||||
distribution or collaboration partners | 23.00% | 23.00% | ||
Accounts Receivable [Member] | Collaborator D [Member] | ||||
distribution or collaboration partners | [1] | 23.00% | ||
[1] | Not greater than 10%. |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies - Calculation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Net loss | $ (6,545) | $ (7,403) | $ (13,151) |
Less gain on changes in fair value of warrant liability | (1,311) | ||
Net loss, diluted | $ (7,856) | $ (7,403) | $ (13,151) |
Weighted average shares outstanding, basic (in shares) | 16,921 | 15,324 | 9,408 |
Net loss per share, basic (in dollars per share) | $ (0.39) | $ (0.48) | $ (1.40) |
Effect of dilutive warrants (in shares) | 137 | ||
Weighted average shares outstanding, diluted (in shares) | 17,058 | 15,324 | 9,408 |
Net loss per share, diluted (in dollars per share) | $ (0.46) | $ (0.48) | $ (1.40) |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies - Outstanding Stock Options and Stock Warrants Excluded From the Diluted Net Loss Per Share Computation (Details) - shares shares in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Stock options (in shares) | 3,374 | 3,504 | 2,054 |
Employee Stock Option [Member] | |||
Stock options (in shares) | 3,374 | 2,960 | 1,489 |
Warrant [Member] | |||
Stock options (in shares) | 544 | 565 |
Note 3 - Fair Value Measureme_3
Note 3 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Fair Value Adjustment of Warrants | $ (1,311) | $ 101 | $ 2,099 |
Note 3 - Fair Value Measureme_4
Note 3 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Cash equivalents | $ 103 | $ 101 |
Restricted cash held as a certificate of deposit | 324 | 324 |
Deposit held as a certificate of deposit | 151 | 150 |
Total assets | 578 | 575 |
Warrant liability | 178 | 1,489 |
Total liabilities | 178 | 1,489 |
Fair Value, Inputs, Level 1 [Member] | ||
Cash equivalents | 103 | 101 |
Restricted cash held as a certificate of deposit | 324 | 324 |
Deposit held as a certificate of deposit | 151 | 150 |
Total assets | 578 | 575 |
Warrant liability | ||
Total liabilities | ||
Fair Value, Inputs, Level 2 [Member] | ||
Cash equivalents | ||
Restricted cash held as a certificate of deposit | ||
Deposit held as a certificate of deposit | ||
Total assets | ||
Warrant liability | ||
Total liabilities | ||
Fair Value, Inputs, Level 3 [Member] | ||
Cash equivalents | ||
Restricted cash held as a certificate of deposit | ||
Deposit held as a certificate of deposit | ||
Total assets | ||
Warrant liability | 178 | 1,489 |
Total liabilities | $ 178 | $ 1,489 |
Note 3 - Fair Value Measureme_5
Note 3 - Fair Value Measurements - Fair Value of Warrant Liability (Details) - Warrant Liability [Member] - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Fair value of warrant liability | $ 1,489 | $ 1,446 |
Fair value of warrants issued | ||
Fair value of warrants transferred (to) from equity upon exercise | (58) | |
Decrease in fair value on exercise date and December 31 | (1,311) | 101 |
Fair value of warrant liability | $ 178 | $ 1,489 |
Note 4 - Prepaid Expenses and_3
Note 4 - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Prepaid sales rebates | $ 925 | $ 923 |
Rent receivable | 108 | 86 |
Prepaid rent | 130 | 123 |
Prepaid employees’ benefits | 113 | 112 |
Prepaid fleet leasing costs | 75 | 61 |
Prepaid dues and subscription | 130 | 4 |
Other | 279 | 354 |
Total prepaid expenses and other current assets | $ 1,760 | $ 1,663 |
Note 5 - Inventory - Summary of
Note 5 - Inventory - Summary of Inventory (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Jan. 01, 2018 | Dec. 31, 2017 |
Raw materials and supplies | $ 217 | $ 298 | |
Finished goods | 167 | 346 | |
Less: Reserve for excess and obsolete inventory | (104) | (140) | |
Total inventory, net | $ 280 | $ 479 | $ 504 |
Note 6 - Property and Equipme_3
Note 6 - Property and Equipment (Details Textual) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Depreciation, Depletion and Amortization, Total | $ 266 | $ 95 | $ 114 |
Note 6 - Property and Equipme_4
Note 6 - Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Property and equipment, at cost | $ 710 | $ 714 |
Less: accumulated depreciation and amortization | (509) | (243) |
Total property and equipment, net | 201 | 471 |
Equipment [Member] | ||
Property and equipment, at cost | 24 | 24 |
Furniture and Fixtures [Member] | ||
Property and equipment, at cost | 157 | 157 |
Computer Equipment and Software [Member] | ||
Property and equipment, at cost | 385 | 354 |
Production Equipment [Member] | ||
Property and equipment, at cost | 65 | 105 |
Leasehold Improvements [Member] | ||
Property and equipment, at cost | $ 79 | $ 74 |
Note 7 - Accrued Liabilities -
Note 7 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Jan. 01, 2018 | Dec. 31, 2017 |
Employee payroll and benefits | $ 708 | $ 761 | |
Severance/retirement pay | 347 | ||
Distributer fees and discounts | 185 | ||
Sales rebates | 106 | ||
Avenova contract liabilities (see Note 8) | 2,282 | ||
Deferred rent | 101 | 69 | |
Other | 164 | 204 | |
Total accrued liabilities | $ 3,255 | $ 2,838 | $ 1,672 |
Note 8 - Adoption of Topic 60_3
Note 8 - Adoption of Topic 606, "Revenue From Contracts With Customers" (Details Textual) - USD ($) | Jan. 01, 2018 | Jun. 01, 2013 | Feb. 07, 2012 | Apr. 30, 2013 | Jan. 31, 2013 | Oct. 31, 2012 | Sep. 30, 2012 | Jan. 31, 2012 | Oct. 31, 2012 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2014 |
Revenue, Remaining Performance Obligation, Amount | $ 41,000 | |||||||||||
Contract with Customer, Liability, Revenue Recognized | 1,453,000 | |||||||||||
Reallocated from Deferred Revenue [Member] | ||||||||||||
Stockholders' Equity, Period Increase (Decrease), Total | $ 600,000 | |||||||||||
Technology Service [Member] | Accounting Standards Update 2014-09 [Member] | ||||||||||||
Contract with Customer, Liability, Total | $ (1,960,000) | |||||||||||
Technology Service [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member] | ||||||||||||
Contract with Customer, Liability, Total | $ 2,000,000 | |||||||||||
Avenova Product [Member] | ||||||||||||
Contract with Customer, Liability, Total | 600,000 | |||||||||||
Avenova Product [Member] | Retained Earnings [Member] | ||||||||||||
Cumulative Effect on Retained Earnings, Net of Tax, Total | 700,000 | |||||||||||
Avenova Product [Member] | Accounting Standards Update 2014-09 [Member] | ||||||||||||
Contract with Customer, Liability, Total | $ (1,300,000) | |||||||||||
China Pioneer [Member] | ||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 2,500,000 | |||||||||||
Unit Purchase Agreement Shares Per Unit | 1 | |||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 | |||||||||||
Excess Fair Value Over Proceeds Received From Purchase | $ 1,000,000 | |||||||||||
China Pioneer [Member] | Tranche One [Member] | ||||||||||||
Purchase Agreement Units | 800,000 | |||||||||||
China Pioneer [Member] | Tranche Two [Member] | ||||||||||||
Purchase Agreement Units | 1,200,000 | |||||||||||
Purchase Agreement Unit Price Per Share | $ 1.25 | |||||||||||
Purchase Unit Agreement Total Units Fair Value | $ 3,500,000 | |||||||||||
China Pioneer [Member] | Neutrophase [Member] | ||||||||||||
Proceeds from Collaborators | $ 312,500 | $ 312,500 | $ 625,000 | |||||||||
Maximum Possible Sales Discounts | $ 500,000 | |||||||||||
Integrated Healing Technologies, LLC [Member] | Neutrophase [Member] | ||||||||||||
Proceeds from Collaborators | $ 750,000 | |||||||||||
Virbac [Member] | Auriclosene (NVC-422) [Member] | ||||||||||||
Proceeds from Collaborators | $ 250,000 | |||||||||||
Principal Business Enterprise, Inc. [Member] | Neutrophase [Member] | ||||||||||||
Proceeds from Collaborators | $ 200,000 | |||||||||||
China Pioneer and Principal Business Enterprise Inc. [Member] | Samples and Future Products [Member] | ||||||||||||
Revenue, Remaining Performance Obligation, Amount | 41,000 | |||||||||||
McKesson Corporation [Member] | Avenova Product [Member] | ||||||||||||
Contract with Customer, Liability, Revenue Recognized | 11,000,000 | 13,600,000 | ||||||||||
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member] | ||||||||||||
Contract with Customer, Liability, Total | $ 2,400,000 | |||||||||||
McKesson Corporation [Member] | Avenova Product [Member] | Calculated under Revenue Guidance in Effect before Topic 606 [Member] | ||||||||||||
Contract with Customer, Liability, Total | $ 1,300,000 |
Note 8 - Adoption of Topic 60_4
Note 8 - Adoption of Topic 606, "Revenue From Contracts With Customers" - Reconciliation of Assets and Liabilities (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Jan. 01, 2018 | |
Accounts receivable | $ 3,385 | $ 3,629 | $ 4,159 | |
Inventory | 280 | 504 | 479 | |
Accrued liabilities | 3,255 | 1,672 | 2,838 | |
Deferred revenue | 41 | 75 | 75 | |
Deferred revenue, non-current | 534 | |||
Accumulated deficit | (114,981) | (111,074) | (108,436) | |
Total net sales | 12,508 | 18,230 | $ 11,897 | |
Cost of product sales | 1,503 | 2,784 | 2,464 | |
Loss from operations | (7,871) | (7,311) | (10,982) | |
Net loss | $ (6,545) | $ (7,403) | $ (13,151) | |
Earnings Per Share, Basic, Total | $ (0.39) | $ (0.48) | $ (1.40) | |
Earnings Per Share, Diluted, Total | $ (0.46) | $ (0.48) | $ (1.40) | |
Accounts receivable | $ 774 | $ (1,509) | $ (1,585) | |
Inventory | 198 | 369 | 472 | |
Accounts payable and accrued liabilities | 516 | (260) | (2,356) | |
Deferred revenue | (34) | $ (472) | $ 1,641 | |
Calculated under Revenue Guidance in Effect before Topic 606 [Member] | ||||
Accounts receivable | 3,027 | 3,629 | ||
Inventory | 316 | 504 | ||
Accrued liabilities | 1,276 | 1,672 | ||
Deferred revenue | 3,894 | 2,841 | ||
Deferred revenue, non-current | 534 | |||
Accumulated deficit | (117,177) | (111,074) | ||
Total net sales | 12,939 | |||
Cost of product sales | 1,492 | |||
Loss from operations | (7,429) | |||
Net loss | $ (6,103) | |||
Earnings Per Share, Basic, Total | $ (0.36) | |||
Earnings Per Share, Diluted, Total | $ (0.43) | |||
Inventory | $ 187 | |||
Accounts payable and accrued liabilities | (328) | |||
Deferred revenue | 550 | |||
Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Accounting Standards Update 2014-09 [Member] | ||||
Accounts receivable | (358) | 530 | ||
Inventory | 36 | (25) | ||
Accrued liabilities | (1,979) | 1,166 | ||
Deferred revenue | 3,853 | (2,766) | ||
Deferred revenue, non-current | (534) | |||
Accumulated deficit | (2,196) | $ 2,638 | ||
Total net sales | 431 | |||
Cost of product sales | (11) | |||
Loss from operations | 442 | |||
Net loss | $ 442 | |||
Earnings Per Share, Basic, Total | $ 0.03 | |||
Earnings Per Share, Diluted, Total | $ 0.03 | |||
Accounts receivable | $ (172) | |||
Inventory | (11) | |||
Accounts payable and accrued liabilities | (844) | |||
Deferred revenue | $ 584 |
Note 8 - Adoption of Topic 60_5
Note 8 - Adoption of Topic 606, "Revenue From Contracts With Customers" - Changes in Assets and Liabilities (Details) $ in Thousands | 12 Months Ended |
Dec. 31, 2018USD ($) | |
Contract Liabilities: Deferred Revenue, Balance at beginning of the period | $ 75 |
Contract Liabilities: Deferred Revenue, additions | |
Contract Liabilities: Deferred Revenue, deductions | (34) |
Contract Liabilities: Deferred Revenue, Balance at the end of the period | 41 |
Contract Liabilities: Accrued Liabilities,Balance at beginning of the period | 1,458 |
Contract Liabilities: Accrued Liabilities, additions | 13,716 |
Contract Liabilities: Accrued Liabilities, deductions | (12,817) |
Contract Liabilities: Accrued Liabilities, Balance at the end of the period | 2,357 |
Contract Liabilities, Balance at beginning of the period | 1,533 |
Contract Liabilities, additions | 13,716 |
Contract Liabilities, deductions | (12,851) |
Contract Liabilities, Balance at the end of the period | $ 2,398 |
Note 8 - Adoption of Topic 60_6
Note 8 - Adoption of Topic 606, "Revenue From Contracts With Customers" - Total Revenues (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Amounts included in contract liabilities at the beginning of the period | $ 1,453 | ||
New activities in the period | 11,055 | ||
Total revenue | $ 12,508 | $ 18,230 | $ 11,897 |
Note 8 - Adoption of Topic 60_7
Note 8 - Adoption of Topic 606, "Revenue From Contracts With Customers" - Revenue Recognized (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Total sales, net | $ 12,508 | $ 18,230 | $ 11,897 |
License Collaboration and Distribution Agreements [Member] | |||
Total sales, net | 203 | 2,059 | |
Technology Service [Member] | License Collaboration and Distribution Agreements [Member] | |||
Total sales, net | 34 | 103 | |
Product [Member] | |||
Total sales, net | 12,474 | 18,127 | $ 11,617 |
Product [Member] | License Collaboration and Distribution Agreements [Member] | |||
Total sales, net | $ 169 | $ 1,956 |
Note 9 - Commitments and Cont_3
Note 9 - Commitments and Contingencies (Details Textual) | Aug. 24, 2016ft² | Dec. 31, 2018USD ($) | Dec. 31, 2017USD ($) | Dec. 31, 2016USD ($) | Jul. 11, 2016ft² |
Area of Property in Sublease Agreement | ft² | 16,465 | ||||
Operating Leases, Rent Expense, Net, Total | $ 385,000 | $ 389,000 | $ 938,000 | ||
Deferred Rent Credit | 286,000 | 355,000 | |||
Operating Leases, Future Minimum Payments Receivable, Current | 690,000 | ||||
Operating Leases, Future Minimum Payments Receivable, in Two Years | 577,000 | ||||
Master Fleet Lease Agreement [Member] | |||||
Operating Leases, Rent Expense, Net, Total | $ 120,000 | $ 94,000 | |||
Number of Vehicles Leased | 54 | ||||
Lessee, Operating Lease, Term of Contract | 3 years | ||||
Lease Agreement, Monthly Payment | $ 14,000 | ||||
Lease Agreement, Management Fee Per Vehicle | 15 | ||||
Lease Agreement, Initial Payment Per Vehicle | $ 3,000 | ||||
KBSIII Towers [Member] | |||||
Lessee Leasing Arrangements, Operating Leases, Square Feet of Property | ft² | 7,799 | ||||
Lessee, Operating Lease, Renewal Term | 5 years | ||||
Lessee Leasing Arrangements, Operating Leases, Earliest Period Prior to Expiration of Current Term to Renew Lease | 1 year | ||||
Lessee Leasing Arrangements, Operating Leases, Latest Period Prior to Expiration of Current Term to Renew Lease | 270 days |
Note 9 - Commitments and Cont_4
Note 9 - Commitments and Contingencies - Future Minimum Lease Payments (Details) $ in Thousands | Dec. 31, 2018USD ($) |
2019 | $ 1,116 |
2020 | 1,025 |
2021 | 438 |
2022 | 75 |
2023 | |
Thereafter | |
Total lease commitment | $ 2,654 |
Note 10 - Warrant Liability (De
Note 10 - Warrant Liability (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | Aug. 01, 2016 | May 05, 2016 | Apr. 04, 2016 | Feb. 16, 2016 | Oct. 27, 2015 | Oct. 27, 2015 | Oct. 22, 2015 | Mar. 03, 2015 | Oct. 31, 2015 | Jul. 31, 2011 | Jun. 30, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Sep. 29, 2016 | Sep. 28, 2016 | Feb. 29, 2016 | Dec. 31, 2015 | Mar. 31, 2015 | Jan. 05, 2012 |
Noncash or Part Noncash Acquisition, Noncash Financial or Equity Instrument Consideration, Warrants Issued | 139,520 | |||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 33.25 | $ 1.81 | $ 1.81 | $ 1.81 | $ 1.81 | $ 3.15 | $ 19.50 | $ 5.19 | ||||||||||||||
Minimum Common Stock Closing Bid Price Per Share | $ 66.50 | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,518,567 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 363,523 | 3,613,284 | 363,523 | |||||||||||||||||||
Warrants and Rights Outstanding | $ 178 | $ 1,489 | ||||||||||||||||||||
Class of Warrant or Right, Exercised During Period | 363,523 | 3,613,284 | 21,000 | 3,977,000 | ||||||||||||||||||
Proceeds from Warrant Exercises | $ 900 | $ 6,600 | $ 38 | $ 7,429 | ||||||||||||||||||
Private Placement [Member] | ||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,094,241 | 4,079,058 | 6,173,299 | |||||||||||||||||||
Underwriting Agreement [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 5 | $ 5 | ||||||||||||||||||||
Warrants and Rights Outstanding, Term | 5 years | 5 years | ||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 492,000 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 442,802 | 442,802 | ||||||||||||||||||||
Proceeds from Issuance of Stock and Warrants | $ 2,100 | |||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,300 | $ 1,300 | ||||||||||||||||||||
Shares Issued, Price Per Share | $ 5 | $ 5 | ||||||||||||||||||||
March 2015 Short-term and Long-term Warrants [Member] | ||||||||||||||||||||||
Length of Notice for warrant Holders | 20 days | 2 days | ||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 21,000 | |||||||||||||||||||||
Class of Warrant or Right, Exercised During Period | 21,000 | |||||||||||||||||||||
Proceeds from Warrant Exercises | $ 38 | |||||||||||||||||||||
Warrant Liabilities, Fair Value Disclosure | 58 | |||||||||||||||||||||
Fair Market Value of Warrants Transferred to Equity Upon Exercise | $ 58 | |||||||||||||||||||||
Short-term Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 15 | |||||||||||||||||||||
Warrants and Rights Outstanding | 28 | |||||||||||||||||||||
Short-term Warrants [Member] | Private Placement [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 1 year 90 days | |||||||||||||||||||||
Long-term Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 16.25 | |||||||||||||||||||||
Warrants and Rights Outstanding | $ 28 | |||||||||||||||||||||
Long-term Warrants [Member] | Private Placement [Member] | ||||||||||||||||||||||
Warrants and Rights Outstanding, Term | 5 years | |||||||||||||||||||||
The 2011 and March 2015 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 5 | |||||||||||||||||||||
Warrants to be Exercised at Lower Price Stock Price Trigger | 5 | |||||||||||||||||||||
Class of Warrant or Right Price Protection Provision Exchangeable Securities Exercise Price Trigger | $ 5 | |||||||||||||||||||||
Warrants and Rights Outstanding | $ 1,800 | $ 1,800 | ||||||||||||||||||||
July 2011, March 2015, and October 2015 Warrants [Member] | ||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1.81 | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 363,523 | 3,613,284 | 363,523 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period | 363,523 | 3,613,284 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ 900 | $ 6,900 | ||||||||||||||||||||
Warrant Liabilities, Fair Value Disclosure | 500 | 1,600 | $ 500 | |||||||||||||||||||
Fair Market Value of Warrants Transferred to Equity Upon Exercise | $ 500 | $ 1,600 |
Note 10 - Warrant Liability - T
Note 10 - Warrant Liability - The Key Assumptions Used to Value the Warrants (Details) | Dec. 31, 2018 | Dec. 31, 2017 |
Measurement Input, Price Volatility [Member] | The 2011 Warrants [Member] | ||
Warrants assumptions | 0.77 | 0.91 |
Measurement Input, Price Volatility [Member] | Short-term Warrants [Member] | ||
Warrants assumptions | 0.77 | 0.91 |
Measurement Input, Price Volatility [Member] | Long-term Warrants [Member] | ||
Warrants assumptions | 0.77 | 0.91 |
Measurement Input, Price Volatility [Member] | October 2015 Warrants [Member] | ||
Warrants assumptions | 0.73 | 0.9 |
Measurement Input, Expected Term [Member] | The 2011 Warrants [Member] | ||
Warrants assumptions | 1.18 | 2.18 |
Measurement Input, Expected Term [Member] | Short-term Warrants [Member] | ||
Warrants assumptions | 1.18 | 2.18 |
Measurement Input, Expected Term [Member] | Long-term Warrants [Member] | ||
Warrants assumptions | 1.18 | 2.18 |
Measurement Input, Expected Term [Member] | October 2015 Warrants [Member] | ||
Warrants assumptions | 1.83 | 2.83 |
Measurement Input, Risk Free Interest Rate [Member] | The 2011 Warrants [Member] | ||
Warrants assumptions | 0.026 | 0.0191 |
Measurement Input, Risk Free Interest Rate [Member] | Short-term Warrants [Member] | ||
Warrants assumptions | 0.026 | 0.0191 |
Measurement Input, Risk Free Interest Rate [Member] | Long-term Warrants [Member] | ||
Warrants assumptions | 0.026 | 0.0191 |
Measurement Input, Risk Free Interest Rate [Member] | October 2015 Warrants [Member] | ||
Warrants assumptions | 0.0251 | 0.0196 |
Measurement Input, Expected Dividend Rate [Member] | The 2011 Warrants [Member] | ||
Warrants assumptions | 0 | 0 |
Measurement Input, Expected Dividend Rate [Member] | Short-term Warrants [Member] | ||
Warrants assumptions | 0 | 0 |
Measurement Input, Expected Dividend Rate [Member] | Long-term Warrants [Member] | ||
Warrants assumptions | 0 | 0 |
Measurement Input, Expected Dividend Rate [Member] | October 2015 Warrants [Member] | ||
Warrants assumptions | 0 | 0 |
Measurement Input, Share Price [Member] | The 2011 Warrants [Member] | ||
Warrants assumptions | 0.0029 | 0.0272 |
Measurement Input, Share Price [Member] | Short-term Warrants [Member] | ||
Warrants assumptions | 0.0024 | 0.0242 |
Measurement Input, Share Price [Member] | Long-term Warrants [Member] | ||
Warrants assumptions | 0.0029 | 0.0272 |
Measurement Input, Share Price [Member] | October 2015 Warrants [Member] | ||
Warrants assumptions | 0.0038 | 0.0286 |
Note 10 - Warrant Liability - O
Note 10 - Warrant Liability - Outstanding Warrant Liability (Details) - USD ($) shares in Thousands, $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 |
Shares (in shares) | 544 | 544 | 565 | 1,458 |
Warrant liability | $ 178 | $ 1,489 | ||
The 2011 Warrants [Member] | ||||
Shares (in shares) | 49 | |||
Warrant liability | $ 15 | |||
Long-term Warrants [Member] | ||||
Shares (in shares) | 96 | |||
Warrant liability | $ 28 | |||
Short-term Warrants [Member] | ||||
Shares (in shares) | 115 | |||
Warrant liability | $ 28 | |||
October 2015 Warrants [Member] | ||||
Shares (in shares) | 284 | |||
Warrant liability | $ 107 | |||
July 2011, Long-term, Short-term, and October 2015 Warrants [Member] | ||||
Shares (in shares) | 544 | |||
Warrant liability | $ 178 |
Note 11 - Stockholders' Equit_3
Note 11 - Stockholders' Equity (Deficit) (Details Textual) $ / shares in Units, $ in Thousands | Sep. 29, 2016USD ($)$ / shares | Aug. 01, 2016USD ($)shares | May 05, 2016USD ($)shares | Apr. 04, 2016USD ($)$ / sharesshares | Feb. 16, 2016USD ($)$ / sharesshares | Dec. 18, 2015 | Dec. 11, 2015 | Mar. 31, 2018USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Sep. 30, 2016USD ($)shares | Dec. 31, 2018USD ($)$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Jun. 04, 2018shares | Jun. 03, 2018shares | Sep. 28, 2016$ / shares | Aug. 31, 2016shares | May 31, 2016shares | Feb. 29, 2016$ / shares | Dec. 31, 2015$ / shares | Jul. 31, 2011$ / shares |
Common Stock, Shares Authorized | 50,000,000 | 240,000,000 | 50,000,000 | 240,000,000 | |||||||||||||||||
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 | |||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 0 | 0 | |||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,518,567 | ||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 2,800 | $ 5,984 | |||||||||||||||||||
Private Placement, Commission Percentage | 6.00% | 6.00% | 6.00% | 6.00% | |||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | $ 0.01 | |||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 363,523 | 3,613,284 | 363,523 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 3.15 | $ 1.81 | $ 1.81 | $ 1.81 | $ 1.81 | $ 19.50 | $ 5.19 | $ 33.25 | |||||||||||||
Proceeds from Warrant Exercises | $ | $ 900 | $ 6,600 | $ 38 | $ 7,429 | |||||||||||||||||
Class of Warrant or Right, Exercised During Period | 363,523 | 3,613,284 | 21,000 | 3,977,000 | |||||||||||||||||
Warrants Exercised, Commission Paid | $ | $ 32 | $ 338 | $ 32 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price, Discount from Market Price | 16.00% | ||||||||||||||||||||
Fair Value Adjustment of Warrants | $ | $ (1,311) | $ 101 | $ 2,099 | ||||||||||||||||||
General and Administrative Expense [Member] | |||||||||||||||||||||
Fair Value Adjustment of Warrants | $ | $ 270 | ||||||||||||||||||||
April 2016 Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,047,121 | 2,039,530 | |||||||||||||||||||
July 2011, March 2015, and October 2015 Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 363,523 | 3,613,284 | 363,523 | ||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1.81 | ||||||||||||||||||||
Proceeds from Warrant Exercises | $ | $ 900 | $ 6,900 | |||||||||||||||||||
Class of Warrant or Right, Exercised During Period | 363,523 | 3,613,284 | |||||||||||||||||||
Mr. Fu [Member] | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 696,590 | ||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 1.81 | ||||||||||||||||||||
Common Stock, Closing Price, Discount | 5.00% | ||||||||||||||||||||
Pioneer Pharma Co. [Member] | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 696,590 | ||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 1.91 | ||||||||||||||||||||
Mr. Sieczkarek [Member] | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 125,387 | ||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 1.91 | ||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,094,241 | 4,079,058 | 6,173,299 | ||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | ||||||||||||||||||||
Sale of Stock, Consideration Received on Transaction | $ | $ 4,000 | $ 7,800 | $ 11,800 | ||||||||||||||||||
Private Placement [Member] | April 2016 Warrants [Member] | |||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,047,121 | 2,039,530 | 3,086,651 | ||||||||||||||||||
Warrants and Rights Outstanding, Term | 4 years | ||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1.91 | ||||||||||||||||||||
Number of Sequential Trading Days | 5 days | ||||||||||||||||||||
Private Placement [Member] | April 2016 Warrants [Member] | Minimum [Member] | |||||||||||||||||||||
Common Stock, Closing Price | $ / shares | $ 4 | ||||||||||||||||||||
Private Placement [Member] | China Kington Asset Management Co. Ltd. [Member] | |||||||||||||||||||||
Private Placement, Commission Percentage | 6.00% | 6.00% | |||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 618 | $ 155 | $ 359 | ||||||||||||||||||
Private Placement [Member] | OP Financial Investments Limited [Member] | |||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,700,000 | ||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 5,984 | ||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | ||||||||||||||||||||
Private Placement [Member] | NYSE American [Member] | |||||||||||||||||||||
Payments of Stock Issuance Costs | $ | $ 34 | ||||||||||||||||||||
Reverse Stock Split [Member] | |||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 25 | 25 |
Note 11 - Stockholders' Equit_4
Note 11 - Stockholders' Equity (Deficit) - Outstanding Warrants (Details) - $ / shares | 3 Months Ended | 12 Months Ended | |||
Dec. 31, 2016 | Sep. 30, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Outstanding warrants (in shares) | 544,000 | 565,000 | 1,458,000 | ||
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ 1.81 | $ 1.81 | $ 5.19 | ||
Warrants granted (in shares) | 3,087,000 | ||||
Warrants granted, weighted average exercise price (in dollars per share) | $ 1.91 | ||||
Warrants exercised (in shares) | (363,523) | (3,613,284) | (21,000) | (3,977,000) | |
Warrants exercised, weighted average exercise price (in dollars per share) | $ 1.81 | $ 1.95 | |||
Warrants expired (in shares) | (3,000) | ||||
Warrants expired, weighted average exercise price (in dollars per share) | $ 78.13 | ||||
Outstanding warrants (in shares) | 565,000 | 544,000 | 544,000 | 565,000 | |
Outstanding warrants, weighted-average exercise price (in dollars per share) | $ 1.81 | $ 1.81 | $ 1.81 | $ 1.81 |
Note 12 - Equity-based Compen_3
Note 12 - Equity-based Compensation (Details Textual) - USD ($) | Mar. 21, 2018 | Mar. 20, 2018 | May 26, 2016 | Mar. 30, 2015 | Jan. 31, 2017 | Jan. 31, 2016 | Jan. 31, 2014 | Jan. 31, 2013 | Jan. 31, 2012 | Jan. 31, 2011 | Jan. 31, 2010 | Dec. 31, 2017 | Sep. 30, 2017 | Dec. 31, 2017 | Jun. 30, 2017 | Dec. 31, 2016 | Jun. 30, 2016 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2018 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 31, 2007 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | 4,000 | 68,000 | 0 | |||||||||||||||||||||
Proceeds from Stock Options Exercised | $ 11,000 | $ 185,000 | $ 0 | |||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 0 | $ 116,000 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,118,000 | 1,616,000 | 1,227,000 | |||||||||||||||||||||
Payments of Dividends, Total | $ 0 | |||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ 671,000 | $ 2,542,000 | $ 1,751,000 | |||||||||||||||||||||
Employees and Directors [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,085,000 | 1,529,000 | 1,139,000 | |||||||||||||||||||||
Nonemployees [Member] | ||||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ 0 | $ 243,000 | $ 262,000 | |||||||||||||||||||||
Employee Stock Option [Member] | ||||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ 671,000 | $ 2,371,000 | $ 1,489,000 | |||||||||||||||||||||
Employee Stock Option [Member] | Resigned Directors [Member] | ||||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ 58,000 | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Exercisable Period | 4 years | 90 days | ||||||||||||||||||||||
Employee Stock Option [Member] | Chief Financial Officer [Member] | ||||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ 260,000 | $ 244,000 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Exercisable Period | 3 years | 90 days | ||||||||||||||||||||||
Employee Stock Option [Member] | Mr. Liu [Member] | ||||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ 26,000 | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Exercisable Period | 3 years | 90 days | ||||||||||||||||||||||
Employee Stock Option [Member] | Nonemployees [Member] | ||||||||||||||||||||||||
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued | 33,000 | 86,000 | 89,000 | |||||||||||||||||||||
Employee Stock Options and RSUs [Member] | ||||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total | $ 1,700,000 | $ 1,700,000 | ||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 3 years 3 days | |||||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 12,000 | 49,000 | 104,000 | |||||||||||||||||||||
Restricted Stock Units (RSUs) [Member] | Employee [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 12,000 | 10,000 | 64,000 | |||||||||||||||||||||
Restricted Stock [Member] | Nonemployees [Member] | ||||||||||||||||||||||||
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued | 0 | 8,000 | 41,000 | |||||||||||||||||||||
Fully Vested Registered Stock [Member] | Nonemployees [Member] | ||||||||||||||||||||||||
Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued | 31,000 | |||||||||||||||||||||||
The 2007 Omnibus Incentive Plan [Member] | ||||||||||||||||||||||||
Common Stock, Capital Shares Reserved for Future Issuance | 40,000 | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Maximum Annual Increase in Shares Authorized | 40,000 | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock | 4.00% | 4.00% | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized | 1,124,826 | 82,461 | 32,646 | 59,157 | 40,000 | 37,427 | 37,207 | |||||||||||||||||
Increase (Decrease) in Number of Shares Available for Grant | 610,774 | 139,449 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 2,318,486 | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum | 10.00% | |||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||||||||||||||||||||
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 100.00% | |||||||||||||||||||||||
The 2007 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% | |||||||||||||||||||||||
The 2007 Omnibus Incentive Plan [Member] | Maximum [Member] | Incentive Stock Options (ISOs) [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||||||||||||
The 2017 Omnibus Incentive Plan [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase in Shares Authorized, Percentage of Outstanding Common Stock | 4.00% | 4.00% | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 2,318,486 | 2,318,486 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 1,188,485 | 1,188,485 | ||||||||||||||||||||||
The 2017 Omnibus Incentive Plan [Member] | Incentive Stock Options (ISOs) [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percentage of Stock Owned by Shareholder, Minimum | 10.00% | |||||||||||||||||||||||
The 2017 Omnibus Incentive Plan [Member] | Employee Stock Option [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 4 years | |||||||||||||||||||||||
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 100.00% | |||||||||||||||||||||||
The 2017 Omnibus Incentive Plan [Member] | Minimum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent | 110.00% | |||||||||||||||||||||||
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||||||||||||
The 2017 Omnibus Incentive Plan [Member] | Maximum [Member] | Shareholder of More Than 10% [Member] | Incentive Stock Options (ISOs) [Member] | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 5 years |
Note 12 - Equity-based Compen_4
Note 12 - Equity-based Compensation - Stock Options Outstanding (Details) - USD ($) $ / shares in Units, $ in Thousands | 12 Months Ended | |||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | |
Outstanding awards (in shares) | 2,960,000 | 1,489,000 | 388,000 | |
Outstanding, weighted-average exercise price (in dollars per share) | $ 5.16 | $ 8.38 | $ 32.03 | |
Outstanding, weighted-average remaining contractual life (Year) | 8 years 73 days | 8 years 219 days | 8 years 255 days | 6 years 73 days |
Outstanding, aggregate intrinsic value | $ 8 | $ 2,586 | $ 702 | $ 19 |
Options granted (in shares) | 1,118,000 | 1,616,000 | 1,227,000 | |
Options granted, weighted-average exercise price (in dollars per share) | $ 2.03 | $ 3.03 | $ 2.74 | |
Options exercised (in shares) | (4,000) | (68,000) | 0 | |
Options exercised, weighted-average exercise price (in dollars per share) | $ 2.35 | $ 2.72 | ||
Options forfeited/cancelled (in shares) | (116,000) | |||
Options forfeited/cancelled, weighted-average exercise price (in dollars per share) | $ 5.12 | $ 22.08 | $ 28.27 | |
Restricted stock units cancelled (in shares) | (701,000) | (87,000) | ||
Outstanding awards (in shares) | 3,374,000 | 2,960,000 | 1,489,000 | 388,000 |
Outstanding, weighted-average exercise price (in dollars per share) | $ 4.13 | $ 5.16 | $ 8.38 | $ 32.03 |
Vested and expected to vest (in shares) | 2,898,000 | |||
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ 4.40 | |||
Vested and expected to vest, weighted-average remaining contractual life (Year) | 8 years 73 days | |||
Vested and expected to vest, aggregate intrinsic value | $ 8 | |||
Vested (in shares) | 1,675,000 | |||
Vested, weighted-average exercise price (in dollars per share) | $ 5.96 | |||
Vested, weighted-average remaining contractual life (Year) | 7 years 146 days | |||
Exercisable (in shares) | 1,675,000 | |||
Exercisable, weighted-average exercise price (in dollars per share) | $ 5.96 | |||
Exercisable, weighted-average remaining contractual life (Year) | 7 years 146 days | |||
Restricted Stock Units (RSUs) [Member] | ||||
Restricted stock units granted (in shares) | 12,000 | 49,000 | 104,000 | |
Restricted stock units granted, weighted-average exercise price (in dollars per share) | ||||
Restricted stock units vested (in shares) | (39,000) | (114,000) | ||
Restricted stock units vested, weighted-average exercise price (in dollars per share) | ||||
Restricted stock units cancelled (in shares) | (11,000) |
Note 12 - Equity-based Compen_5
Note 12 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Employees and Directors (Details) - Employees and Directors [Member] - $ / shares | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Expected price volatility | 89.30% | 87.78% | 84.47% |
Expected term (Year) | 5 years 357 days | 6 years 328 days | 7 years 10 days |
Risk-free interest rate | 2.80% | 2.12% | 1.57% |
Dividend yield | 0.00% | 0.00% | 0.00% |
Weighted-average fair value of options granted during the period (in dollars per share) | $ 1.51 | $ 2.34 | $ 2.06 |
Note 12 - Equity-based Compen_6
Note 12 - Equity-based Compensation - Weighted-average Assumptions Used in Determining the Value of Options Granted to Non-employees (Details) - Nonemployees [Member] - $ / shares | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Expected price volatility | 85.03% | 87.41% | 87.68% |
Expected term (Year) | 10 years | 10 years | 10 years |
Risk-free interest rate | 2.94% | 2.27% | 1.61% |
Dividend yield | 0.00% | 0.00% | 0.00% |
Weighted-average fair value of options granted during the period (in dollars per share) | $ 1.99 | $ 2.40 | $ 2.29 |
Note 12 - Equity-based Compen_7
Note 12 - Equity-based Compensation - Summary of Stock-based Compensation Expense Included in Results of Operations (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Stock-based compensation expense | $ 671 | $ 2,542 | $ 1,751 |
Research and Development Expense [Member] | |||
Stock-based compensation expense | 32 | 113 | 195 |
Selling and Marketing Expense [Member] | |||
Stock-based compensation expense | 141 | 152 | 132 |
General and Administrative Expense [Member] | |||
Stock-based compensation expense | $ 498 | $ 2,277 | $ 1,424 |
Note 13 - Employee Benefit Pl_2
Note 13 - Employee Benefit Plan (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
The 401(k) Plan [Member] | ||
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 14,000 | $ 0 |
Note 14 - Income Taxes (Details
Note 14 - Income Taxes (Details Textual) | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | 35.00% |
Domestic Tax Authority [Member] | ||
Open Tax Year | 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 | |
State and Local Jurisdiction [Member] | ||
Open Tax Year | 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 |
Note 14 - Income Taxes - Federa
Note 14 - Income Taxes - Federal and State Income Tax Provisions (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Current | |||
Federal | |||
State | 4 | 3 | 2 |
Total current tax expense | 4 | 3 | 2 |
Deferred | |||
Federal | |||
State | |||
Other | |||
Total deferred tax expense | |||
Income tax provision | $ 4 | $ 3 | $ 2 |
Note 14 - Income Taxes - Summar
Note 14 - Income Taxes - Summary of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands | Dec. 31, 2018 | Dec. 31, 2017 |
Deferred tax assets: | ||
Net operating losses | $ 26,790 | $ 25,564 |
Accruals | 446 | 225 |
Deferred revenue | 10 | 508 |
Stock options | 1,425 | 1,556 |
Other deferred tax assets | 716 | 727 |
Property and equipment | 9 | |
Total deferred tax assets | 29,396 | 28,580 |
Property and equipment | (35) | |
Total deferred tax liabilities | (35) | |
Valuation allowance | (29,396) | (28,545) |
Net deferred taxes |
Note 14 - Income Taxes - Valuat
Note 14 - Income Taxes - Valuation Allowance (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Label | $ 851 | $ (10,100) | $ 3,642 |
Note 14 - Income Taxes - Summ_2
Note 14 - Income Taxes - Summary of Net operating Loss and Tax Credit Carryforwards (Details) $ in Thousands | Dec. 31, 2018USD ($) |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Not Subject to Expiration [Member] | |
Net operating losses | $ 5,216 |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Expiration Years 2024 - 2037 [Member] | |
Net operating losses | 94,886 |
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Expiration Years 2026 - 2035 [Member] | |
Tax credits | 1,316 |
State and Local Jurisdiction [Member] | Not Subject to Expiration [Member] | |
Tax credits | 325 |
State and Local Jurisdiction [Member] | Expiration Years 2028 - 2037 [Member] | |
Net operating losses | $ 84,078 |
Note 14 - Income Taxes - Effect
Note 14 - Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Income tax provision (benefit) at federal statutory rate | $ (1,374) | $ (2,516) | $ (4,471) |
State tax | 20 | (12) | (157) |
Stock based compensation expense for GAAP | 283 | 154 | 52 |
Change in valuation allowance | 851 | (10,484) | 3,641 |
Revaluation of warrant liability | (275) | 34 | 806 |
Tax credits | (31) | ||
Other | 33 | (49) | 162 |
Section 162(m) disallowance | (88) | 336 | |
Tax Reform - Tax Rate Change | 12,540 | ||
Impact of ASC 606 | 554 | ||
Total | $ 4 | $ 3 | $ 2 |
Note 14 - Income Taxes - Unreco
Note 14 - Income Taxes - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands | 12 Months Ended | |
Dec. 31, 2018 | Dec. 31, 2017 | |
Unrecognized benefit - beginning of period | $ 931 | $ 974 |
Gross increases/ (decreases) - prior/current period tax positions | 43 | (43) |
Unrecognized benefit - end of period | $ 974 | $ 931 |
Note 15 - Related Party Trans_2
Note 15 - Related Party Transactions (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Accounts Receivable, Related Parties | $ 39,000 | $ 0 | |
China Pioneer [Member] | |||
Revenue from Related Parties | 27,000 | $ 418,000 | |
China Pioneer [Member] | Selling and Marketing Expense [Member] | |||
Related Party Costs | 426,000 | 102,000 | 0 |
China Kingston [Member] | Related-party Commission Fees [Member] | |||
Related Party Transaction, Expenses from Transactions with Related Party | $ 400,000 | $ 0 | $ 1,100,000 |
Note 16 - Subsequent Events (De
Note 16 - Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($) | Mar. 25, 2019 | Feb. 28, 2019 | Feb. 27, 2019 |
China Kingston [Member] | |||
Brokering Fee, Percent | 2.00% | ||
Consulting Agreement, Amount | $ 100,000 | ||
Consulting Agreement, Term | 1 year | ||
Triton [Member] | |||
Share Purchase Agreement, Authorized Amount | $ 3,000,000 | ||
Share Purchase Agreement, Donation Fee, Shares | 150,000 | ||
Payments of Stock Issuance Costs | $ 15,000 | ||
Iliad Research and Trading, L.P. [Member] | |||
Proceeds from Convertible Debt | $ 2,000,000 | ||
Debt Instrument, Convertible, Conversion Price | $ 1.65 | ||
Iliad Research and Trading, L.P. [Member] | Convertible Debt [Member] | |||
Debt Instrument, Face Amount | $ 2,215,000 | ||
Debt Instrument, Interest Rate, Stated Percentage | 10.00% | ||
Debt Instrument, Collateral Amount | $ 1,000,000 | ||
Notes Payable, Other Payables [Member] | Pioneer Pharma Co. [Member] | |||
Debt Instrument, Face Amount | $ 1,000,000 | ||
Interest Payable | $ 150,000 |